Identification of putative target genes of miR-106b, miR-93, miR-25 in medulloblastoma. by Ng, Hin Yi Winnie. & Chinese University of Hong Kong Graduate School. Division of Anatomical and Cellular Pathology.
Identification of Putative Target 
Genes of miR-106b，miR-93， 
miR-25 in Medulloblastoma 
NG，Hin Yi Winnie 
A Thesis Submitted in Partial Fulfillment of 
the Requirements for the Degree of 
Master of Philosophy 
in 
Anatomical and Cellular Pathology 




First and foremost, I would like to express my sincere thanks to my supervisor, Dr. 
K. M. Lau for accepting me into his laboratory. In addition to his patient guidance and 
directions for my project, I truly thank for his understanding and constant trust through 
these past years. 
I wish to express my gratitude to Prof. H. K. Ng for his professional supervision, 
1 
sharing of vast knowledge, and giving me the opportunities to participate in 
departmental events & conferences through which I have gained a lot of invaluable 
experience. 
I also have to thank the folks in 5/F Cancer Centre, and especially my teammates 
for their friendship. I will never forget the cheers we have shared. 
Last but not least, I would like to express my deepest appreciation to my family for 
their endless love and support, all of which I will treasure forever. 
ii 
LIST OF TABLES 
Table 1.1 Aberrant miRNA expression in MB 14 
Table 3.1 Primers used in real-time PGR amplification for potential target genes 
39 
Table 3.2 Cloning constructs of the potential target genes 40 
Table 3.3 Primers sequences and specific annealing temperature for 3'UTR 
cloning 41 
Table 3.4 Primers for site-directed mutagenesis 46 
Table 3.5 Number of predicted target genes from different prediction programs54 
Table 3.6 Common predicted targets among the seven prediction programs 55 
Table 4.1 Components of “ 1 ®^-round"-reverse transcription buffer 81 
‘ Table 4.2 Components of "2"''-round"-reverse transcription buffer 83 
Table 4.3 Sequences of adaptors and primers 85 
Table 4.4 Reagents for PGR amplification 87 
Table 4.5 PGR amplification condition 87 
Table 4.6 Primers used in real-time PGR amplification for ZNF793 & CLN8... 92 
Table 4.7 PGR primers for 3'UTR cloning 93 
Table 4.8 Primers for site-directed mutagenesis of CLN8 94 
Table 4.9 Statistical summary of the cDNA library 97 
Table 4.10 Blast result for potential sequences 97 
iii 
LIST OF FIGURES 
Figure 3.1 Schematic flowchart for the computational approach 26 
Figure 3.2 Taqman stemloop qRT-PCR analyses of miRNA expression levels in 
MB cell lines and normal cerebellum 50 
Figure 3.3 Transfection efficiency using Lipofectamine 2000 51 
Figure 3.4 Inhibitory effect of anti-miRNAs 53 
Figure 3.5 Quantitative real-time PGR for candidate genes 56 
Figure 3,6 Changes in target gene expression in DAOY 58 
Figure 3.7 Relative luciferase activity ofpMIR-ZNFXl and pMIR-DNAJB 12 .. 60 
Figure 3.8 Luciferase constructs with mutations at microRNA target sites 64 
1 
Figure 3.9 Site-directed mutagenesis of 3'UTR 65 
Figure 3.10 Western Blotting ofZNFXl 66 
Figure 4.1 Schematic diagram of the biochemical method 78 
Figure 4.2 Preparation of cell extracts 80 
� Figure 4.3 Reverse transcription using endogenous miRNAs as primers 81 
Figure 4.4 Second-strand cDNA synthesis 83 
Figure 4.5 Restriction enzyme digestion 84 
Figure 4.6 Ligation of adaptor 85 
Figure 4.7 PCR amplification with biotin-labelled miRNA primers 87 
Figure 4.8 Final round of PCR amplification 89 
Figure 4.9 Cloning potential sequence into the pCR2.1 vector 90 
Figure 4.10 Final construct of a cDNA clone 96 
Figure 4.11 Blast result for ZNF793 and CLN8 : 99 
Figure 4.12 Quantitative real-time PCR for candidate genes 101 
Figure 4.13 Changes in mRNA level upon treatment with miRNA inhibitors 102 
Figure 4.14 Relative luciferase activity of ZNF793-pMIR and CLN8-pMIR...... 103 
iv 
Figure 4.15 Mutation construct for CLN8-pMIR 106 
Figure 4.16 Site-directed mutagenesis of CLN8 3'UTR 106 
Figure 5.1 Effects of inhibition of miR-106b-25 cluster on cell growth 120 
Figure 5.2 Cell cycle progression profile 121 
Figure 5.3 IC50 for cisplatin in DAOY 123 
Figure 5.4 Cell growth after treatment with cisplatin 124 
Figure 5.5 Effect of inhibition of miR-106b-25 cluster on cell proliferation……125 
Figure 5.6 Wound healing assays 127 
Figure 5.7 Efficiency of over-expression of miR-106b mimic on cell growth... 129 ‘ 
I Figure 5.8 Effects of miR-106b inhibition or over-expression on cell growth …130 
XV 
ABSTRACT 
Medulloblastoma (MB) is a brain malignancy with high incidence in childhood. 
It is often classified by its morphology and immunohistochemical features; however, 
the pathogenesis of MB still remains elusive. In the past decades, more emphasis has 
been put onto elucidating the molecular aspect contributing to the pathogenesis of MB, 
and in which microRNAs (miRNAs) are found to be key regulators involved. 
Therefore, investigating the relationships between microRNA and MB lay the basic 
1 
groundwork for understanding tumour biology. MicroRNA expression analysis can 
lead to identification of candidate miRNAs that may play important roles in 
medulloblastoma carcinogenesis. It is also important to identify target genes that are 
� associated with these known aberrant miRNA expression. Currently there are several 
approaches in identifying potential targets of miRNAs, which include a variety of 
bioinformatic prediction programs, as well as experimental techniques (Dalmay 2008). 
Bioinformatic prediction programs predict miRNA targets mainly based on the degree 
of complementarity between the miRNAs and their targets; as a consequence, they 
often result in extensive lists of putative target genes that include many false positives. 
On the other hand, experimental techniques usually involve series of complicated 
experimental procedures, and are time consuming. Therefore, identification of target 
genes still remains as a challenging task. My project focuses on the identification of 
vi 
putative target genes that are associated with the aberrant expression of miR-106b-25 
cluster in medulloblastoma. The project mainly consists of three parts: 1) target 
prediction of miR-106b-25 cluster using bioinformatics; 2) miR-106b-25 cluster target 
identification using experimental techniques; 3) functional studies on miR-106b-25 
cluster in MB. 
1) Target Prediction Using Bioinformatics: 
In an attempt to narrow down the list of potential downstream targets for 
I 
miR-106b-25 cluster, we have combined the prediction results from seven 
bioinformatic programs and have selected out only common genes that appeared in all 
of the seven prediction programs. This approach allowed us to narrow down to 
� ZNFXl as a candidate gene for miR-106b and miR-93. Validation of ZNFXl was 
confirmed using luciferase reporter assay. Upon inhibition of miR-106b，and miR-93, 
significant decrease in luciferase activity was observed. Site-direct mutagenesis on 
the conserved recognition site at on the 3'UTR of ZNFXl further confirmed 
specific interactions between miR-106b & miR-93 and ZNFXl. Collectively, these 
data suggest that ZNFXl is a potential target gene for miR-106b and miR-93. 
2) Experimental Technique in Identifying Target Genes: 
Adopting the experimental approach of using miRNAs as endogenous primers in 
series of reverse transcription reactions, we hope to create a library of clones from 
vii 
which we could isolate individual clones that possess partial sequence of potential 
target genes for miR-106b. By screening 96 clones from our library, we have 
identified ZNF793 and CLN8 as potential target genes for miR-106b. Through 
luciferase reporter assay and subsequent site-direct mutagenesis at the deduced 
miR-106b recognition site, we have successfully confirmed CLN8 as a target gene 
regulated by miR-106b. 
3) Functional Studies on miR-106b-25 Cluster in Medulloblastoma: 
1 
MicroRNAs have been implicated in biological processes, including cell 
development, cell proliferation, apoptosis，and tumorigenesis. MTT assay revealed 
that silencing the activity of the miR-106b-25 cluster with specific inhibitors resulted in 
， a decrease in cell growth in MB cell lines (ONS-76 & DAOY). However, there was no 
shift in cell cycle distribution observed. Upon inhibition of the miR-106b-25 cluster, 
decrease in cell proliferation and migration were observed in DAOY. These data 
suggest that the miR-106b-25 cluster may be involved in cellular pathways that are 
responsible for the tumorigenesis of MB. 
In conclusion, using a combination of prediction programs and experimental 
techniques, we were able to identify potential target genes for the miR-106b-25 cluster. 
The deregulation of miRNA expression may contribute to the development of MB 
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CHAPTER 1: INTRODUCTION 
1.1 Medulloblastoma (MB) 
1.1.1 Definition of Medulloblastoma 
Medulloblastoma is the most common malignant brain tumour of childhood 
(Lee et al. 2001). It accounts for about 25% of all pediatric brain tumours, and there 
are approximately 500 cases diagnosed in the US each year (Hjalmars et al. 1999). It 
I 
has a slightly higher incidence in boys than girls (Polkinghom and Tarbell 2007). 
Patients often present with symptoms such as headaches, morning vomiting, and ataxia; 
MRI imaging typically reveals a well-defined enhancing mass locating at the posterior 
fossa (Polkinghom and Tarbell 2007). The tumour usually arises from midline vermis 
and may invade into the fourth ventricle or through the floor of the ventricle to the 
brainstem (Halperin 1986). Medulloblastoma has the propensity to metastasize and 
disseminate through the subarachnoid space with approximately 30% of patients 
diagnosed with cerebrospinal fluid (CSF) metastasis (Fouladi et al. 1999). Patients 
with medulloblastoma are generally stratified into two risk categories, "standard-risk" 
and "high-risk". Stratification is mainly based on three criteria: 1) age at diagnosis; 2) 
degree of surgical resection; and 3) disease spread (Dhall 2009). Long-term survival 
1 
rate reaches approximately 85% for standard-risk patients who are above the age of 3， 
and for high-risk patients, the survival rate is lowered to approximately 70% (Dhall 
2009). However, patients who are below the age of 3，particularly infants, are at 
significantly higher risk for suffering severe side-effects from treatments (Dhall 2009). 
1.1.2 Pathological Classification 
According to the WHO classification, medulloblastoma is classified as one of 
the five embryonal tumours (Polkinghorn and Tarbell 2007). For years, classification 
1 
based on morphological features has caused great controversy due to the fact that 
medulloblastoma is histogenetically indistinguishable from other central nervous 
system (CNS) embryonal tumors; as a consequence, they were collectively called 
peripheral neuroectodermal tumours (PNETs) (Polkinghorn and Tarbell 2007). 
Despite the controversy, morphological classification forms the foundation on which 
current pathological diagnosis still rest (Huse and Holland 2010). On the basis of their 
histopathological features, medulloblastomas are separated into the classic tumours and 
four variants, which include medulloblastoma with extensive nodularity (MBEN), 
desmoplastic/nodular (D/N), anaplastic, and large cell medulloblastoma (Ellison 2010). 
This scheme of classification proves to have clinical utility. For instance, MBENs 
and D/N medulloblastomas have better outcome in. infants than classic tumours, while 
2 
anaplastic and large cell medulloblastomas are more aggressive (Ellison 2010). As 
there are increasing recognitions of medulloblastoma as a heterogeneous disease, 
researchers are shifting their approach to develop a classification system based on 
molecular classification. Many reports have demonstrated that medulloblastoma has 
molecular phenotypes distinct from other brain tumours, such as primitive 
neuroectodermal tumours, atypical teratoid/rhabdoid tumours, and malignant gliomas 
(Pomeroy et al. 2002). 
1 
1.1.3 Current Treatment 
Medulloblastoma was once thought a fatal disease; it was only following the 
introduction of intensive craniospinal irradiation in 1969 that the 5-year survival rate 
improved to approximately 32% (Bloom et al. 1969). Nowadays, treatment usually 
involves a combination of surgery, radiation therapy, and chemotherapy depending on 
the risk stratification of individual patients (Polkinghom and Tarbell 2007). As a 
result, today approximately 60% of patients with medulloblastomas are free of 
progressive disease 5 years after diagnosis (Lee et al. 2001). Relatively speaking, 
compared to malignant glioma, radiation and chemotherapy are generally more 
successful in combating medulloblastoma; however, these conventional treatment are 
often accompanied with long-term side effects (Huse and Holland 2010). Of those 
3 
who survived, nearly all patients suffer side effects from radiation to different extent, 
which include cognitive impairment, psychiatric disorders, endocrine dysfunction, and 
skeletal growth retardation (Polkinghom and Tarbell 2007). Despite the seemingly 
favourable survival rates, the adverse therapeutic effects from treatment still remain a 
serious concern. There is no doubt that clinical and morphological classification has 
laid the groundwork for standard treatment regimens, yet risk stratification for 
treatment merely based on clinical parameters proves to have shortcomings. Perhaps 
the new challenge lies towards compiling a "tailor-made" treatment for individual 
patients as influential factors such as the aggressiveness of the tumour and the 
sensitivity to treatment varies from different individuals (Ellison 2010). To better 
improve the treatment outcome and ameliorating adverse effects caused by standard 
treatments, more emphasis is needed to put onto the molecular pathogenesis of 
medulloblastoma. In other words, the ultimate goal is to provide molecular definition 
to medulloblastoma in addition to morphological classification. 
1.1.4 Molecular Pathology 
To improve upon the current clinical risk stratification and aiming at 
minimizing side effects from treatments, scientists have worked on unraveling the 
molecular basis of medulloblastoma in order to better understand the pathogenesis of 
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this tumour. In fact, an extensive literature now exists on the molecular biology of 
medulloblastoma. Aberrant activation of several cell-signaling pathways has been 
implicated in MB development: 1) the Sonic hedgehog cascade (Shh), accounting for 
approximately 25% of medulloblastoma, 2) the Wingless signaling pathway (Wnt), 
accounting for approximately 15% of the tumours (Polkinghom and Tarbell 2007)，and 
3) ERBB signaling (Gilbertson 2004). 
Shh signaling has been found to have critical roles in the development of the 
I 
CNS such as driving the proliferation in the granule neuron precursors of the 
cerebellum (Huse and Holland 2010). As various murine models have demonstrated 
that medulloblastoma tumours are resulted from perturbation of granule cells (Marino 
2005), granule cell progenitors (GCPs) remain as the main focus for the source of 
medulloblastomas. During normal development, granule cells undergo massive 
expansion in the external granule layer shortly after birth (Polkinghom and Tarbell 
2007); however, dysregulated granule cell development is observed to be associated 
with overactive SHH signaling in GCPs. PTCHl, SMO, and SUFU mutations 
together resulted in the aberrant activation of the Shh pathway, thereby re-initiate 
proliferation of the GCPs (Polkinghom and Tarbell 2007). These expanding cells 
would exit the cell cycle, migrate into the inner zone of the external granule layer, and 
eventually differentiate in the internal granule layer forming the tumour mass 
5 
(Polkinghom and Tarbell 2007). 
Another mechanism by which Shh signaling contributes to medulloblastoma 
formation is via the upregulation of MYCN expression (Kenney et al. 2003). 
Upregulation of MYCN activates D-type cyclins, while represses the expression of 
other cyclin-dependent kinase inhibitors, and thus disrupting cell-cycle control 
(Knoepfler and Kenney 2006). Degradation of MYCN is accomplished via 
phosphorylation by glycogen synthase kinase-3 beta (GSK3p); in other words, 
I 
inhibition of GSK3p results in increased MYCN levels and thus eventually contributes 
to the formation of medulloblastoma. 
Other pathways involved in medulloblastoma pathogenesis include the Wnt 
�• pathway (Huse and Holland 2010). It is associated with defects in APC, a tumor 
suppressor gene which keeps the Wnt signaling pathway in check (Pfister et al. 2010). 
In fact, activating point mutations in CTNNBl which encodes for P-catenin result in 
preventing GSK3-(3 to phosphorylate p-catenin (Pfister et al. 2010). As a result, upon 
such activation, p-catenin accumulates in the nucleus and activates series of 
transcription factors, and subsequent downstream targets including MYC and cyclin 
D1 (Polkinghom and Tarbell 2007). 
Members of ERBB can trigger the cell-signal pathways of mitogen-activated 
protein kinase (MAPK), AKT, and STAT, which in turns regulate cell proliferation, 
6 
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apoptosis，migration, and differentiation (Gilbertson 2004). In fact, ERBB2 might 
have a role in MB formation, in a study with more than 150 pediatric MB patients, 
ERBB2 protein expression was shown in 80% of the tumour samples, whereas healthy 
cells in the cerebellum do not express ERBB2 at any stage during development 
(Gilbertson 2004). High expression of ERBB2 is likely contributing to tumor 
development by interacting through the complex network of homodimers and 
heterodimers, activating ERKl/2 and AKT signals, as well as upregulating prometastic 
1 
genes when overexpressed in MB (Gilbertson 2004). Taken together, aberrant 
molecular alterations in critical pathways (either through excess signaling or absence of 
appropriate inhibitory signals) play an important part in medulloblastoma 
� tumorigenesis. These tremendous progresses in the field of molecular biology of 
medulloblastoma are of great help in forming the basis of molecular risk stratification 
in the near future. 
1.1.5 Molecular Classification of MB 
As mention previously, better molecular understanding may benefit clinical 
classification and prognostication of MB; in fact, there are increasing number of studies 
that use gene expression data to identify distinct molecular subgroups in MB 
(Thompson et al. 2006). Based on their transcriptome, WNT- and SHH-driven MB 
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was demonstrated to be comprised of two very distinct biological subgroups with 
distinctive expression signatures (Pfister et al. 2010). More specifically, CTNNBl 
mutation and monosomy 6 were found to be associated with the WNT-driven tumours, 
while PTCH/SUFU mutation, and 9q deletion were found to be associated with the 
SHH-driven tumours (Pfister et al. 2010). Five molecular subtypes were identified by 
Kool et al. using mRNA expression data of MB: the two most distinct subtypes (WNT 
or SHH signaling), as well as Kool type C，D, and E (Kool et al. 2008). Kool type C 
I 
and D tumours are characterized by elevated expression of neuronal differentiation 
genes, while Kool type D and E tumours are associated with photoreceptor genes 
expression (Kool et al. 2008). Others such as Northcott et al. had also analyzed gene 
� expression profiles of MB and identified same molecular subgroups, with the exception 
that Kool type C and D tumours were now categorized as one subgroup called 
Northcott group D (Northcott et al. 2010). Furthermore, Northcott et al. had identified 
specific protein markers for each subgroup: CTNNBl for WNT tumours, GLIl for 
SHH tumours, NPR3 for Northcott group C tumours, and KCNAl for group D tumours, 
all of these can be used for immunohistochemical assay for high accuracy classification 
(Northcott et al. 2010). Together, these findings can be linked to clinical follow-up 
data for prognostication of MB, and be used for developing targeted therapies for each 
subtype separately. 
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1.2 MicroRNAs (miRNAs) 
1.2.1 Biogenesis 
MicroRNAs are a class of single-stranded RNA molecules that range from 17 to 
27 nucleotides in length (Visone and Croce 2009). Biogenesis of microRNAs begins 
in the nucleus where transcription of the primary transcript takes place. The primary 
microRNA transcripts (pri-miRNAs) are transcribed from the genome by RNA 
polymerase II (Visone and Croce 2009). Following the transcription, pri-miRNAs 
fold into a stem-loop structure, and are enzymatically cut by Drosha into smaller 
fragments that are about 70 nucleotides in length forming the hairpin structure which 
� now called the pre-miRNAs (Visone and Croce 2009). Pre-miRNAs are exported to 
the cytoplasm by Exportin-5 (Visone and Croce 2009). Subsequently they are cleaved 
by the Dicer into imperfect double-strand RNAs forming the duplex-designated 
miRNAs. One of the strands from the duplex is selected to function as a mature 
microRNA, while the other strand is degraded (Visone and Croce 2009). After series 
of processing from the primary transcripts and sequential modification steps, the 
mature microRNAs are incorporated into the RNA-induced silencing complexes (RISC) 
ready to function as regulators (Orom and Lund 2010). 
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1.2.2 Functions 
MicroRNAs act as gene regulators through incorporating into the RISC, and 
together as a complex, it binds onto the mRNA sequence of the target genes that are 
either perfectly or partially complementary to itself (Dalmay 2008). It is suggested 
that perfect complementarity leads to mRNA degradation, while partial 
complementarity leads to inhibition of translation (Visone and Croce 2009). Although 
the degree of homology shared by the microRNA and its targets varies, often a region 
1 
called the seed region, starting from the to the nucleotide at the 5’ region of the 
microRNA, shows almost complete complementarity between the two (Dalmay 2008). 
Not only that microRNAs are found to directly regulate target gene expression by 
transcriptional degradation or post-translational repression, they are also suggested to 
be involved in fine-tuning expression of target genes rather than completely switching 
off their expression (Dalmay 2008). 
1.2.3 MicroRNAs & Cancers 
Ever since the discovery of human microRNAs, extensive research has focused on 
revealing their functions and regulations in cancers. Numerous reports have 
demonstrated the involvement of microRNA-mediated regulation in proliferation, 
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apoptosis, differentiation and cellular development (Kloosterman and Plasterk 2006). 
There are several mechanisms as to how microRNA expression can be altered, which 
include chromosomal abnormalities, epigenetic changes, mutations and 
polymorphisms (SNPs), and defects in microRNA biogenesis machinery (Visone and 
Croce 2009). The first evidence of aberrant microRNA expression profile in human 
cancers was demonstrated in B-cell chronic lymphocytic leukemia (Calin et al. 2002). 
Chromosomal deletion at the 13ql4 locus resulted in the loss or reduction of miR-15 
1 
and miR-16 expression, and led to the discovery of genes linked to the disease (Calin et 
al. 2002). Another example of miRNA and its oncogenic roles is the overexpression of 
miR-155 and its link to several types of lymphomas (Eis et al. 2005). Transgenic mice 
� with overexpression of miR-155 in B cells were found to develop preleukemic 
lymphoproliferative disease, which eventually progressed to B-cell leukemia (Eis et al. 
2005). Subsequent microarray study of the malignant B cells revealed several 
deregulated protein-coding genes that are identified as potential targets of miR-155， 
indicating that deregulation of miR-155 could be involved in early events in 
oncogenesis (Eis et al. 2005). In addition to their oncogenic roles, microRNAs are 
found to contribute to tumorigenesis by modulating the expression of proteins that 
control cellular function and cell death decisions (Visone and Croce 2009). For 
example, the up-regulation of miR-221/222 has been reported to target and pSV''''' 
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proteins, which are key regulators binding to Cdk/cyclin complexes responsible for 
inhibition of the Gi/S phase switch (Visone et al. 2007; Fomari et al. 2008). 
MicroRNAs are not only found to participate in early events in oncogenesis and 
intermediate steps in tumorigenesis, they are also found to participate in later steps such 
as metastases (Visone and Croce 2009). In a recent study, it was found that 
suppressing miR-21 in metastatic breast cancer cells can significantly reduce the 
invasiveness and metastatic properties of the cancer cells (Visone and Croce 2009). 
I 
Collectively, microRNAs are found to be involved in different types of cancers, 
emerging as important regulatory factors. 
1.2.4 Aberrant Expressions of MicroRNAs in Medulloblastoma 
As thousands of microRNAs being identified, several reports have shown 
evidence for a role of microRNA in tumorigenesis of medulloblastoma. It was first 
reported by Pierson et al that decreased expression of miR-124 was observed in 
medulloblastoma, and responsible for modulating cell-cycle regulation by targeting 
CDK6 to slow tumour cell growth (Pierson et al. 2008). Other microRNAs involve in 
MB tumorigenesis include miR-92, miR-19a, and miR-20, all of which were found to 
be overexpressed in hedgehog-active medulloblastoma (Turner et al. 2010). These 
microRNAs are all encoded by the miR-17/92 cluster and their expressions were found 
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to be associated with a variety of cancers (Turner et al. 2010). The expression of 
miR-17/92 was most elevated in MB with activated Shh signaling and associated with 
the elevated c-Myc and n-Myc; in other words, may enhance the growth potential of 
MB(Tumer et al. 2010). Other medulloblastoma-related microRNAs such as miR-31 
and miR-153 were found to have direct association between their expression and 
disease severity (Turner et al. 2010). There are many more examples showing 
evidence of microRNA being involved in medulloblastoma; altogether, these studies 
I 
indicate that microRNA-mediated regulations of important cellular pathways are 
important factors contributing to medulloblastoma pathogenesis. 
1.2.5 MiR-106b-25 Cluster in Medulloblastoma 
Preliminarily, our team has investigated the involvements of miRNAs in MB by 
employing miRMAX microarray analysis for quantitatively profiling of 182 miRNAs 
in MB cell lines (DAOY and D283) and 4 clinical samples, and compared the profiles 
to age-matched normal cerebellum samples. The data indicated upregulation of 17 
miRNAs and downregulation of 9 miRNAs expression in MB (Table 1.1), of which 
miR-93 had a fold-change of �6.4，and miR-25 had a fold-change of �4.6，while a trend 
of increased level of miR-106b was also found. Hierarchical clustering analysis of 
these differentially expressed miRNAs demonstrated pattern of association among 
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these miRNAs (Data not shown). The expression profiles of miR-106b, miR-93, and 
miR-25 were verified by real-time stem loop PGR assays in an extended panel of MB 
samples, and results showed strong correlation with the microarray data (Pearson 
correlation coefficient R=0.92, p<0.03) (Data not shown). Our preliminary data 
clearly demonstrated that aberrant expression of miR-106b-25 cluster is found in MB. 
Table 1.1 Aberrant miRNA expression in MB 
1 
Upregulated miRNAs 
Gene symbol Normal Medulloblastoma Fold Permutation 
Cerebellum changes p-value 
[ i S S i i S i i i S m i P S M l i l l S l l i l l l E S l " " ^ ^ " ^ 
Hsa-miR-122a 15.4 418.4 27.2 0.0022 
i S S i i l i l i i S i l i i i i i l l i l i l l l S l S S ] 
‘ Hsa-miR-144 2.3 51.4 22.3 0.0022 
Hsa-miR-155 13.0 288.8 22.3 0.0022 
Hsa-miR-182 12.1 648.5 53.8 0.0022 
[ l l l l i l i p i H i 
Hsa-miR-19a 14.3 225.6 15.8 0.0022 , 
Hsa-miR-25 561.4 2608.7 . 4.6 0.0022 
“[盡讓 1 1 1 1 2 «鍾 _ : _塑函•二 J 勝 … J 
Hsa-miR-371 2.4 73.7 30.7 0.0022 
. M ^ S i M M l K l i i l l i i ^ 二 : 
Hsa-miR-93 639.3 4105.0 6.4 0.0022 
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Downregulated miRNAs 
Gene symbol Normal Medulloblastoma Fold Permutation 
Cerebellum Changes p-value 
丨 丨 触 基 凝 娥 • 謎 I j j j • 劣 薩 0 . 0 0 2 2 ： ~ 
Hsa-miR-125a 11262.2 1546.9 -7.3 0.0022 
圓 證 腿 • 誦 腿 1 1 « 涵 顯 画 醒 醒 H I ] 
Hsa-miR-128b 2711.4 313.6 -8.6 0.0022 
隱 臓 • 羅 • l i i i i i l l l i i l l l S 漏 i I Z O 
Hsa-miR-31 1216.4 203.7 -6.0 0.0022 
M i i l i i i i i i i M i i i l l l S M Z I E Z S E Z E ] 
Hsa-miR-324-5p 4707 107.7 -4.4 0.0022 
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1.2.6 miR-106b-25 cluster in Regulating Target Genes 
MicroRNA genes can occur in clusters, and transcribed as polycistronic transcripts 
(Li et al. 2009). The miR-106b-25 cluster, which includes miR-106b, miR-93, and 
miR-25, was found differentially expressed in various human cancers. This cluster of 
microRNAs is located on human chromosome 7 in the intron 13 of MCM7 (Li et al. 
2009). MicroRNAs serve as important regulators of gene expression; they can 
function as oncogenes or as tumor suppressors. For example, the transcription factor 
E2F1 was identified as a target gene for miR-106b and miR-93, and possibly have the 
function to prevent excessively high E2F1 expression in HCC (Li et al. 2009). 
Inhibition of miR-106b-25 cluster inhibited cell proliferation, as well as suppressed 
anchorage-independent growth in HCC (Li et al. 2009). In gastric cancers, 
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miR-106b-25 cluster was found to be able to inhibit transforming growth factor-p 
(TGFp)-induced cell cycle arrest (Petrocca et al. 2008). While in mammary epithelial 
cells, miR-106b promoted cell division (Ivanovska et al. 2008; Li et al. 2009). These 
data demonstrate that miR-106b-25 cluster plays an important role in tumorigenesis of 
various cancers. As the mechanisms and pathways targeted by cancer-related 
microRNAs are being uncovered, these discoveries would shed new light on the 
application for these regulatory microRNAs in cancer treatments. 
I 
1.2.7 Applications of Regulatory MicroRNAs 
Extensive analysis showed that aberrant expression of microRNAs contributes to 
� . the tumorigenesis of various cancers. In fact, these dysregulations of microRNAs in 
tumors indicate that microRNAs are promising candidates for distinguishing different 
tumour subtypes, resolving different tumour origins, as well as predicting differential 
stages of tumors (Petrocca et al. 2008). In other words, they may act as useful 
diagnostic tools, prognostic tools, and therapeutic tools. A study conducted by Lu and 
colleagues showed that microRNA profiling could accurately distinguish tumours 
reflecting different mechanisms of transformation in acute lymphoblastic leukemia 
samples (Lu et al. 2005). These microRNA were clustered distinctively in different 
lineages of leukemia, indicating its potential to serve as diagnostic tool (Lu et al. 2005). 
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In fact, microRNA expression profiling has been suggested to be more accurate than 
mRNA expression profiling for resolving the origin of metastasis of unknown primary 
tumor (Visone and Croce 2009), again demonstrating its potentially important 
diagnostic properties. Another interesting finding is that microRNAs seem to 
correlate with cellular differentiation stage. Murakami and colleagues have reported 
that miR-222, miR-106a, and miR-17-92 clusters have been associated with the degree 
of the differentiation of hepatocellular carcinomas (Murakami et al. 2006), suggesting a 
I 
prognostic role of microRNAs. Other proposed microRNA therapeutic strategies such 
as re-expression of miRNAs, anti-miRNAs, and target protectors also hold great 
promise. Several reports have shown that microRNAs are related to drug resistance, 
� and re-expressing miRNAs may be used in treatments that have lost efficacy due to 
drug resistance (Garzon et al. 2008). Anti-miRNAs and miRNA sponges can bind 
specific microRNA and prevent its interaction with its targets (Ebert et al. 2007), while 
target protectors bind to the 3'UTR of specific microRNA target genes to prevent 
access to target sites (Choi et al. 2007). Although these approaches hold great 
promises, they rely heavily on the identity of microRNA target genes. These proposed 
therapeutic approaches will become very useful as more and more targets of 
microRNAs are being identified, yet further studies are necessary to demonstrate their 
efficiency in in vivo models. 
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1.3 Target Gene Identification 
1.3.1 Recent Molecular Advances in Target Gene Identification 
As highlighted in previous sections, microRNAs are important regulators of gene 
expression and thus participate in physiological processes in different cancers. In fact, 
ever since the discovery of microRNA, scientists have been trying different ways to 
identify their targets. There are several different approaches to identify target genes of 
1 
microRNAs. Recall that microRNAs target their target genes through complementary 
base-pairing mechanism; therefore, many target gene identification programs, such as 
BLAST, are based on this idea of "complementary-binding" property (Dalmay 2008). 
‘ However, this may work well in the plant kingdom, but in the animal kingdom 
microRNAs are not perfectly complementary to their targets (Dalmay 2008). 
Experimental target identification is another common approach. It often involves 
either over-expression or down-regulation of microRNAs, then combined with mRNA 
profiling to identify genes that have changed in expression. This method is generally 
referred to as transcriptome analysis (Dalmay 2008). The main advantage of using 
techniques involved with microarrays is the ability to identify a large set of microRNA 
targets at a time. Another means of experimental target identification is through RISC 
purification. This method involves using antibodies against the Argonaute-2 protein, a 
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key component of the RISC, and then followed by subsequent RISC purification 
(Beitzinger et al. 2007). Extracting the mRNA from the purified RISC complexes, 
target genes can be identified through either direct sequencing or microarray 
hybridization (Beitzinger et al. 2007). Ribosomal mRNA profiling is another means 
of experimental target identification. mRNAs that are targeted by miRNAs were 
reported to be associated with polysome, while bound by miRNAs, they would show 
differential polysomal spectrum (Orom and Lund 2010). In fact, Orom and Lund 
I 
proposed that polysome profiling could in part reflect the degree of translation of these 
targeted mRNAs (Orom and Lund 2010). Therefore, mRNAs that are regulated by 
specific endogenous miRNA can be identified by analyzing the shifts in individual 
‘ mRNA abundance in polysome profiles following miRNA overexpression or inhibition 
(Nakamoto et al. 2005). There are still many more approaches in miRNA-mediated 
target identification, and these approaches would help expand the current knowledge of 
miRNA and their target recognition. 
1.3.2 Importance of Target Gene IdentiHcatioii 
It is clear that microRNAs participate in key regulatory networks controlling the 
cell's fate, affecting physiological processes such as differentiation, proliferation, and 
apoptosis. Aberrant expression of microRNAs has found to be closely associated with 
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various cancers including medulloblastoma. The identification of their downstream 
target genes will not only aid in understanding the pathogenesis of medulloblastoma, 
but also guides the development of more effective treatment strategies. Although 
there are several different approaches in identifying target genes, the identification of 
target genes still proves to be rather challenging. It still remains unknown whether one 
approach is better than the other, perhaps probably a combination of these approaches 




CHAPTER 2: AIMS OF STUDY 
Despite tremendous progress in the field of molecular biology of medulloblastoma 
in the past few decades, much remains to be found out in understanding the 
pathogenesis, and critical pathways involved in the tumorigenesis of medulloblastoma. 
As researchers have expanded their focus from morphological classification to 
molecular stratification, microRNA profiling has shed new light on the classification 
system for MB. MicroRNAs are known to be important regulators of gene expression 
responsible for the pathogenesis of many cancers, not surprisingly, medulloblastoma 
tumours too are found to express distinctive pattern of microRNAs. In addition to 
microRNA profiling, identifying downstream target genes regulated by these 
microRNAs is equally important. Taken together that differential microRNA 
expression is implicated in the tumorigenesis of medulloblastoma likely through the 
regulation of oncogene or tumour suppressor gene expressions, these target genes 
regulated by microRNAs are therefore promising candidates useful for potential gene 
therapy or small molecule drugs. However, identifying target genes has proven to be a 
bigger challenge than expected. Given that the miR-106b-25 cluster is found to be 
aberrantly expressed in MB samples and in cell lines, and given the known phenotypic 
effect on cell-cycle demonstrated by miR-106b-25 cluster in other cancers as 
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mentioned in previous sections... in this study, our primary objective is to identify 
putative target genes regulated by the differentially up-regulated miR-106b-25 cluster 
in medulloblastoma. Two different approaches will be used to identify putative target 
genes: 1) computational approach; and 2) experimental approach. In the 
computational approach, seven computational target prediction programs will be used 
to generate a list of putative target genes. By combining the seven prediction lists 
generated using different selection criteria; we hope to narrow down the number of 
1 
target genes by eliminating false positives. In the experimental approach, we will 
adopt a biochemical method previously used to identify target genes regulated by 
microRNAs in C.elegans. The method employs the use of endogenous microRNAs as 
� primers to initiate reverse-transcription to generate cDNAs clones that contain partial 
sequence of the target genes. By sequencing analysis of the library of cDNA clones, 
we hope to experimentally identify target genes of the miR-106b-25 cluster using 
endogenous microRNAs in medulloblastoma cell lines. Lastly, in parallel we would 
like to investigate on the functional roles of miR-106b-25 cluster in medulloblastoma. 
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CHAPTER 3: COMPUTATIONAL TARGET PREDICTION 
3.1 Introduction- Computational Approach 
Based on the fact that microRNAs and their targets share partial complementarity 
and very often complete complementarity in the seed region, many computational 
target prediction programs have been developed to predicted potential target genes 
(Dalmay 2008). There are generally three main types of target sites characterized on 
1 
the basis of the number and position of matching nucleotides between the microRNA 
and its target: 1) 5'-Dominant canonical target sites; 2) 5'-Dominant seed-only target 
sites; and 3) 3'-Compensatory target sites (Sethupathy et al. 2006). 5'-Dominant 
� canonical target sites define targets with perfect complementarity to the seed sequence 
of the microRNA and extensive base-pairing to the rest, while the 5'-Dominant 
seed-only target sites have limited base-pairing with the rest of the microRNA 
(Sethupathy et al. 2006). On the other hand, 3'-Compensatory target sites only have 
extensive base-pairing with the 3' half of the microRNA, but do not have perfect match 
to the seed sequence (Sethupathy et al. 2006). Many target gene identification 
programs such as BLAST, and TargetScan etc., predict target genes based on this idea 
of "complementary-binding" (Dalmay 2008). This may work well in the plant 
kingdom, however, in the animal kingdom microRNAs are not always perfectly 
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complementary to their targets (Dalmay 2008). In other words, the concept of using 
the property of "complementary-binding" would lead to both false positive and false 
negative predictions. Recall that there are different types of complementary 
base-pairing mechanisms as mentioned above; it is not surprising that different 
prediction programs would have their own selection criteria for target genes based on 
different parameters, such as base pairing between the miRNAs and their targets, 
thermodynamic of the miRNA-mRNA duplexes, cross-species sequence comparison, 
I 
and the number of target sites for the miRNA (Watanabe et al. 2007). As a result, it 
would be expected that target prediction lists are extensive and embedded with many 
false positives, and at the same time miss out many false negatives. 
” Although the exact mechanism behind microRNAs and their actions in regulating 
target genes are not completely well understood, computational identification of target 
genes is still an invaluable way to generate lists of putative target genes. Therefore, in 
this chapter, we will be focusing on using the computational approach to identify 
potential target genes regulated by miR-106b-25 cluster in medulloblastoma. Seven 
prediction programs were used to generate the target gene lists for the miR-106b-25 
cluster: 1) EIMMo2; 2) miRDB; 3) miR-Tar-miRanda; 4) miR-Tar-RNAhybrid; 5) 
Diana-microT; 6) Pic-Tar; and 7) TargetScan 4.2. By comparing the lists of target 
genes predicted by all of the seven programs, we hope to select out common target 
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genes that appeared in all of the programs, and ultimately narrowing down the target 
gene lists to a manageable size for experimental validation. The general scheme for 
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Figure 3.1 Schematic flowchart for the computational approach. 
The flowchart summarizes the major steps used to identify potential target genes using 
the computational approach in this chapter. 
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3.2 Methods 
3.2.1 Prediction Algorithms 
A total of seven commonly used prediction algorithms were employed to predict 
common target genes regulated by the miR-106b-25 cluster: 1) EIMMo2; 2) miRDB; 3) 
miR-Tar-miRanda; 4) miR-Tar-RNAhybrid; 5) Diana-microT; 6) Pic-Tar; and 7) 
TargetScan 4.2. Different prediction algorithms have different selection criteria for 
I 
their targets. The following sections provide a brief description for each of the 
algorithm. 
3.2.1.1 EIMMo2 
EIMMo2 focuses on studying the specificity in microRNA-dependent regulation. 
A general Bayesian method was developed for the inference of microRNA target sites, 
and together with explicit models for microRNAs to represent the evolution of the 
orthologous target sites, it allows the program to infer species-specific microRNA 
targeting. 
(Gaidatzis D, van Nimwegen E，Hausser J, Zavolan M: Inference of miRNA targets using 
evolutionary conservation and pathway analysis.) 
3.2.1.2 miRDB 
miRDB is an online database used for predicting microRNA targets. This 
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prediction program is based on support vector machines (SVMs) and high-throughput 
training datasets. By employing the SVMs, which are universal constructive machine 
learning procedures based on statistical learning theory, the goal is to reduce the 
training error and while achieving better generalization on unseen data. 
(Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, EnrightAJ: miRBase: microRNA 
sequences, targets and gene nomenclature.) 
3.2.1.3 miRTar-miRanda 
miRTar is a web server that identifies microRNA targets in the 3'UTR of mRNA of 
I 
mammalian genes for a given input of microRNA. It is generally faster than the other 
search tools. Because of its efficient performance, it is often incorporated with 
powerful microRNA target search tool, such as miRanda and RNAhybrid. miRanda is 
an algorithm for finding genomic targets for microRNAs. It provides a ranked list of 
gene targets, as well as detail analyses of each conserved target gene/sites. 
John B, Enright AJ，Aravin A, Tuschl T, Sander C，Marks DS. Human MicroRNA targets. PLoS Biol. 
2004;2(ll):e363 
3.2.1.4 miRTar-RNAhybrid 
RNAhybrid predicts microRNA targets by finding the minimum free energy 
hybridization for a long and a short RNA. The hybridization takes place in a domain 
mode where the short sequence is hybridized to the best fitting part of the target. 
Marc Rehmsmeier Peter Steffen, Matthias HOchsmann, Robert Giegerich Fast and effective prediction 
ofmicroRNA/target duplexes RNA, 10:1507-1517,2004 
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3.2.1.5 Diana-microT 
Diana-microT is another web-based program based on several parameters 
calculated individually for each of the microRNA, and provides a final prediction score 
by combining conserved and non-conserved microRNA recognition elements. This 
program also reports a signal to noise ratio and a precision score to address the 




Pic-Tar is an algorithm developed for the purpose of identification of microRNA 
� targets. It provides detailed 3'UTR alignment for microRNA and the mRNA with 
predicted sites regarding on different vertebrates, Drosophila species, nematode 
species, and as well as targets that are not conserved but co-expressed in the same 
tissue. 
http://pictar.mdc-berlin.de/ 
3.2.1.7 TargetScan 4.2 
TargetScan searches for the presence of conserved 8mer and 7mer sites. 8mer 
sites are defined as showing complementarity between the mature microRNA to their 
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target(s) with exact match to position 2-8 followed by an "A", while 7mer sites are 
defined as showing exact match to positions 2-8 or 2-7 followed by an "A" of the 
mature microRNA. Predictions are primarily based on complementarity of the seed 
region, it also identifies sites with mismatches in the seed region yet compensated by 
conserved 3’ pairing. 
(Lewis BP, Shih I，Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of mammalian microRNA 
targets.) 
3.2.2 Cell Culture 
3.2.2.1 Cell Lines 
Human medulloblastoma cell line (DAOY) was obtained from the American 
Tissue Culture Collection (Rockville, MD, USA). DAOY cells were cultured using 
MEMa (Gibco Invitrogen Corporation) medium supplemented with 10% of fetal 
bovine serum (FBS) (Gibco Invitrogen Corporation). Cell cultures were maintained in 
a humidified incubator containing 5% CO2 at 37°C. Culture medium was renewed 
every 2 to 3 days. For sub-culturing, DAOY cells were washed twice with Ix 
phosphate buffered saline (Ix PBS) (Sigma Chemical Company), then trysinized using 
tiypsin-EDTA (Gibco Invitrogen Corporation) until cells were detached. 
Trypsinization was terminated with twice volumes of growth medium. Cell pellets 
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were obtained by centrifugation at 1,000 rpm for 3 min at room temperature. Cell 
suspension was re-plated to new culture plates according to their concentrations. 
3.2.2.2 Cell Counts 
10|iL of cell suspension was diluted with equal volume of Trypan blue (Gibco 
Invitrogen Corporation) to distinguish dead cells from viable cells. Then, 10|xL of the 
mixture was injected into hemacytometer, and cells were counted under the microscope. 
The cell concentration was calculated using the average of the four comers on the grid 
I 
of the hemocytometer. 
3.2.3 Transfections 
� All transfections were performed using Lipofectamine 2000 according to the 
manufacturer's recommended concentrations. 
3.2.3.1 Transfection of MicroRNA Inhibitors 
Specific inhibitions of endogenous miR-106b/miR-93/miR-25 were achieved by 
transfection of microRNA inhibitors. Single-stranded microRNA inhibitors 
(anti-miR-106b/anti-miR-93/anti-miR25) and anti-miR negative control#l (negative) 
were acquired from Ambion. Mock experiments included only transfection reagent 
(Lipofectamine 2000) (Gibco Invitrogen Corporation). 
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3.2.3.1.1 Transfection Efficiency of Lipofectamine 2000 
The transfection efficiency of Lipofectamine 2000 (Lipo2000) using the 
manufacturer's recommended concentrations were investigated using FITC-labelled 
double stranded RNA (BLOCK-iT Fluorescent Oligo) (Gibco Invitrogen Corporation). 
1.8x10^ DAOY cells were plated onto 6-well culture plates. After 24hr of incubation 
at 37°C, a total of 100 pmol of BLOCK-iT Oligo were diluted with 250nL of 
Opti-MEM®I Reduced Serum Medium (OPTI-MEM) (Gibco Invitrogen Corporation), 
) 
while 5|iL of Lipo2000 were diluted in 250^iL of OPTI-MEM for 5 min. Then, the two 
were mixed together and incubated for another 20 min at room temperature. After the 
incubation, 500|xL of the mixture was added in drop-wise manner to appropriate wells 
that were refreshed with 2mL of culture medium. FITC signals were detected using a 
fluorescence microscope at 24 hours post-transfection. 
3.2.3.1.2 Transfection of MicroRNA Inhibitors for Real-time PGR 
DAOY cells were plated onto 6-well culture plates in triplicates at 1.5x10^ cells 
per well, and incubated for 24hr at 37°C. A total of 100 pmol of 
anti-miR-106b/anti-miR-93/anti-miR-25 inhibitors were diluted in 250pL of 
OPTI-MEM, while 5|xL of Lipo2000 was diluted in 250nL of OPTI-MEM for 5 min. 
The two were mixed together thoroughly, and incubated for another 20 min. Then, 
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500|j,L of the mixture was added in drop-wise to appropriate wells containing 2mL of 
fresh culture medium. At 24hr post-transfection，the cells were harvested for RNA 
extraction, reverse transcription, and real-time PGR amplification. 
3.2.3.1.3 Transfection of MicroRNA Inhibitors for Western 
Blotting 
3.0x10^ DAOY cells were plated onto 60-mm culture plates for collection of 
protein lysates after treatment with microRNA inhibitors (anti-miR-106b/anti-miR-93/ 
I 
anti-miR-25). After 24hr of incubation at 37°C，a total of 200 pmol of each of the 
microRNA inhibitors were diluted in SOO^L ofOPTI-MEM, while lO i^L of Lipo2000 
was similarly diluted in 500|iL of OPTI-MEM for 5 min. Then, the two were mixed 
� together and incubated for 20 min at room temperature. After the incubation, ImL of 
the mixture was added to appropriate wells that were refreshed with 5mL of culture 
medium. 
3.2.3.2 Co-transfection of Plasmid and MicroRNA Inhibitors 
3.2.3.2.1 Blocking Efficiency of MicroRNA Inhibitors 
The efficiencies of microRNA inhibitors in inhibiting endogenous microRNAs 
were assessed by co-transfecting individual microRNA inhibitors and luciferase 
expression vectors (pMIR) that were cloned with reverse complement sequences of 
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specific microRNA (pMIR-miR-106b/pMIR-miR-93/pMIR-miR-25). The 
efficiencies were tested in DAOY. Co-transfection was preformed according to the 
manufacturers' recommended concentrations. 1.8x10^ DAOY cells were plated onto 
6-well culture plate and incubated at 37°C for 24hr. A total of 50 pmol of microRNA 
inhibitors, lOOOng of pMIR (pMIR-miR-106b/pMIR-miR-93/pMIR-miR-25), and 
lOng of pRL-CMV Renilla luciferase control (pRL) (Promega) were diluted in 250|iL 
ofOPTI-MEM, while 6\iL ofLipo2000 was diluted in 250|xL ofOPTI-MEM for 5 min. 
I 
The two were mixed together and incubated at room temperature for 20 min. After the 
incubation, 500[iL of the mixture was added drop-wise into each well containing 2mL 
of fresh culture medium. At 24hr post-transfection, cells were harvested for 
‘ dual-luciferase assay. 
3.2.3.2.2 Co-transfection of Target Gene Expression Vector and 
MicroRNA Inhibitors 
Co-transfection of microRNA inhibitors and luciferase expression vector cloned 
with the 3'UTR of potential target genes (pMIR) were performed in DAOY according 
to the manufacturer's recommended concentrations. 1.2x1 (>4 cells were plated onto a 
24-well plate, and incubated overnight at 37°C. A total of 150ng of pMIR (cloned 
with 3'UTR of potential target gene), 1 Ong of pRL, and 5 pmol of microRNA inhibitors 
(anti-miR-106/anti-miR-93/anti-miR-25) were diluted in SO i^L of OPTI-MEM, while 
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l|xL of Lipo 2000 was diluted in 50|xL of OPTI-MEM for 5 min. Then the two were 
mixed together and incubated for 20 min. After the incubation, lOOpL of the mixture 
was added to each well containing 500|j,L of fresh culture medium. Cells were 
harvested at 24hr post-transfection for dual-luciferase assay as above. 
3.2.4 Real-time PCR Amplification 
3.2.4.1 Total RNA Extraction from Cell Lines 
I 
Cells were harvested at 80% confluence for RNA extraction. All centrifugations 
at this section were performed at 4°C. Cells were first rinsed with IxPBS. ImL of 
TRIZOL® Reagent (Gibco Invitrogen Corporation) was added to each of the 100mm 
culture dish, and incubated for 5 min at room temperature. 0.2mL of chloroform was 
added to each sample tube and shaked vigorously for 30 sec, and settled for 3 min. 
Subsequently, the samples were centrifuged at 13,000 rpm for 15 min. After the 
mixture had separated into different phases, the aqueous phase was collected and 
precipitated using 0.5mL of isopropanol for 1 hour at -20°C. Following the 
precipitation, the mixture was centrifuged at 13,000 rpm for 10 min. The RNA pellet 
was washed with 75% (v/v) ice-cold ethanol, and air-dried for 15 min. Finally, it was 
re-suspended in SOjxL of RNase free-water. The quantity and quality of the extracted 
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RNA were determined by the NanoDrop Spectrophotometer. The five RNA samples 
for the normal cerebellum were purchased from ATCC. 
3.2.4.2 Stemloop miRNA Taqman qRT-PCR Analysis 
The differentially expressed microRNAs (miR-106b, miR-93, and miR-25) were 
subjected to stemloop miRNA taqman qRT-PCR analysis to check for their expression 
levels in 7 MB cell lines (ONS-76, DAOY，D425, D458, D384, D341 Med, and D283 
Med), and 5 normal cerebellum samples. The stemloop miRNA Taqman qRT-PCR 
I 
in this section was performed using the TaqMan® Reverse Transcription Reagents, 
and TaqMan Universal PGR master mix purchase from Applied Biosystems. 10 ng 
of total RNA from each cell lines was individually subjected to reverse transcription 
(RT) using the specific stem-loop microRNA primers for miR-106b/miR-93/miR25 
and RNU6B (internal reference). lOjiL of the reaction mixture (1.5mM dNTP, 5U of 
Reverse Transcriptase, 1.5x RT Buffer, 0.38U of RNase inhibitor, and 1.5x microRNA 
primers) was incubated on ice for 5 min. The reaction condition was as follows: 
16°C for 30 min; 42°C for 30 min; 85�C for 5 min; and finally terminated at 4°C. 
Following the RT, 0.66|iL of the first strand cDNA was added to the PGR reaction 
mixture (5|iL Taqman® Universal PGR Master Mix, 0.5nL of 20x miRNA Taqman® 
probe) to make up the total of 10|xL reaction volume. The reaction was performed in 
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96-well optical plate, and the PGR condition was as follows: 95°C for 10 min; and 40 
cycles of 95°C for 15 sec and 60°C for 1 min. This step amplifies cDNA using the 
groove binder probe labeled with the FAM reporter dye linked to the 5'end of the 
probe and a non-fluorescence quencher at the 3'end of the probe. Samples were 
prepared in triplicates. The microRNA expressions were normalized using the 
internal reference gene (RNU6B)，and compared relatively to the average of all the 
normal cerebellum samples. 
I 
3.2.4.3 Reverse Transcription 
To study the effect of inhibiting miR-106b/miR-93/miR-25 on the mRNA 
expression level of the potential target genes, RNA collected from DAOY cells 
、• 
previously treated with microRNA inhibitors were subjected to reverse transcription to 
synthesize cDNA for subsequent real-time PGR assays. DAOY cells were first 
transfected with specific miRNA inhibitors as described in section 3.2.3.1. RNAs 
were extracted from cells treated with specific microRNA inhibitors 
(miR-106b/miR-93/miR25) as described in the previous sections. A total of l^ig of 
RNA from each sample was subjected to reverse transcription in a total of 20|xL 
reaction volume (Ix AmpliTaq Gold Buffer, 5mM MgCb, ImM dNTP, 50ng random 
hexamer, lOU RNase inhibitor, SOU of MuLV) (Applied Biosystems). The condition 
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was as follows: 25°C for 10 min; 42°C for 60 min; 95°C for 5 min; and finally 
terminated at 4°C. The cDNA products were kept at -20°C ready for subsequent 
real-time PGR reactions. 
3.2.4.4 Real-time PCR Target Gene Expression 
Real-time PCR assay was used to investigate the gene expression of specific 
target gene in cell lines, and after treatment with microRNA inhibitors (miR-106b, 
I 
miR-93, and miR-25). The primer sequences are listed in Table 3.1. cDNAs 
prepared from the reverse transcription was diluted to 1:44 dilution factor. Using the 
SYBR Green RT-PCR Kit (Applied Biosystems)，4.5^L of the diluted cDNA was 
� mixed with 2x SYBR pre-mixture，0.25 |xM of paired-up sense and antisense primers 
to make up a total of lO i^L reaction volume. The thermo-profile was as follows: 
95°C for 20 sec, 50°C for 2 min, 95°C for 10 min, and 40 cycles of 95�C for 15 sec 
and 60°C for 1 min. Samples were prepared in triplicates, and evaluation of the 
expression levels were normalized to the internal control (RPS3). Cycle threshold 
(Ct) of miRNAs was compared with those of RPS3 to determine relative expression 
level. Relative fold change between expression of miRNAs in the treated and 
control samples was determined by the following equation: fold change: 
where A A Ct=(Cthsa-miR - CtRPS3)treated 一 (CtmiR " CtRPS3)control. 
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Table 3.1 Primers used in real-time PGR amplification for potential target genes 
Target Gene Primers (forward & reverse) 5，—3， 
ZNFX1 TCC TGG AAC AGG CAA AAC CTA T 
GCA CAA TGC TGG TCT TCT GAC A 
1 ^ - 9 3 targets / / � f ： ‘ ： 必 ， ‘ � � 
ZNFX 1 TCC TGG AAC AGG CAA AAC CTA T 
GCA CAA TGC TGG TCT TCT GAC A 
^m^^mm^mmmm^mmmmmmm 
DNAJB12 AGC TGT GAA AAG GGT CAA GCA 
TTG CTG AGT ACC GCA TAT GCT ‘ 
‘ RPS3 AGC CAC CAG AAC ACA GAA TG 
CTA GTG GCC ACC TTT TCA GC 
3.2.5 Cloning of Potential Target Genes into pMIR Luciferase 
‘ Expression Vector 
Genomic fragments containing the 3'UTR of potential target genes were PGR 
amplified using high-fidelity PGR amplification, and then cloned into pMIR luciferase 
expression vector through specific restriction enzyme digestions and ligation. The 
pMIR vectors cloned with specific 3'UTR were then ready for co-transfection with 
microRNA inhibitors and dual luciferase assays. The cloning constructs of the 
potential target genes can be found in Table 3.2. 
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Table 3.2 Cloning constructs of the potential target genes 
ZNFXl 
ID NM_021035 
Total Length of 3，UTR 1365bp 
Conserved Region Number of sites 2 
Location on 3'UTR 484-491 
Location on 3'UTR 1324-1331 .. 
Poorly Conserved Number of sites 2 
‘ Region Location on 3'UTR 134-140 
Location on 3'UTR 979-985 
fmrn^^^mimmsimmmm 
Conserved Region Number of sites 1 
Location on 3'UTR 483-489 
Poorly Conserved Number of sites 1 
� Region Location on 3'UTR 133-139 
DNAJB12 
ID NM_001002762 
Total Length of 3，UTR 2980bp 
Conserved Region Number of sites 1 
Location 2876-2883 
Poorly Conserved Number of sites None 
Region 
*note that the conserved sites are conserved in Human, Mouse, Rat, Dog and Chicken (TargetScan 4.2) 
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3.2.5.1 High-Fidelity PGR Amplification of 3，UTR 
Genomic fragments containing the 3'UTR of the potential target genes were PGR 
amplified using FastStart High Fidelity PGR System (Roche). lOOng of genomic 
DNA was subjected to PGR amplification in a total of 20iiL reaction volume (Ix 
FastStart High Fidelity Reaction Buffer; 1.8mM MgCl2; O.S^M dNTP; 0.4nM of 
forward primer; 0.4|iM of reverse primer; and 2.5U of FastStart High Fidelity Enzyme 
Blend). The cloning primers and the specific annealing temperature for ZNFXl and 
I 
DNAJB12 are listed in Table 3.3. The thermal profile is as follows: 95°C for 2 min; 35 
cycles of 95°C for 30 sec, 58°C or 55�C for 30 sec, and 72°C for 50 sec; 72°C for 7 min; 
and finally terminated at 4°C. 
Table 3.3 Primer sequences and specific annealing temperature for 3'UTR cloning 
Target Primer Sequences (Forward & Start Amplicon Annealing 
Genes Reverse) 5'->3' Site Size Temperature 
f i i i i l M l i l i i i i S ^ ^ 
CCC AAGCTT TTT GGC TGA 28334也 
GTT G C T T C T GA 
^ ^ ^ 騮 羅 誦 _ 爾 爾 • • 羅 • 誦 漏 翻 
‘ — 醒 灘 醒 _ 纖 _ 一 」 
CCC AAGCTT TCA AGA AAT 18777也 
A C A G C T T C C A G A G G 
**The underlined sequences are restriction enzyme sequence. ACTAGT is Spel; AAGCTT is Hindlll. 
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3.2.5.2 PCR Purification of Amplified PCR Product 
The amplified PCR products were subject to purification using the 
PCRquick-spin™ PCR product purification kit (TechDragon Ltd.) according to the 
manufacturer's protocol. In brief, all of the 20\iL from the PCR reaction mixture were 
added to 500|xL of Binding Buffer and incubated for 1 min at room temperature. Then 
the samples were loaded to the spin column and centrifuge at 13,000 rpm for 1 min. 
700|iL of Washing Buffer was added to the column and centrifuged at 13,000 rpm for 1 
I 
min. Then the column was centrifuged again for another minute to dry the membrane. 
50|iL of Elution Buffer was added to the column and incubated for 1 min. The samples 
were collected by centrifugation at 13,000 rpm for 1 min. 
3.2.5.3 Restriction Enzyme Digestions 
In order to insert the PCR amplified 3'UTR into the pMIR luciferase expression 
vector, both the amplified fragments and the pMIR vectors were subjected to restriction 
enzyme digestions. 1 |ig of pMIR vectors and 1 |ag of the purified PCR products were 
separately added to the reaction mixture to make up a total of 20|iL (Ix NEB Buffer 2; 
1 \iL of Hindlll (NEB); and 1 |xL of Spel (NEB)). The enzymatic reaction was allowed 
to incubate overnight at 37°C. 
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3.2.5.4 Ligation of 3'UTR to Expression Vector 
The digested 3'UTRs and pMIR vectors were subjected to another round of 
purification as described in section 3.2.5.2. The 3'UTR fragments and the pMIR 
vector (3:1 ratio) together were diluted in Ix T4 ligation buffer with 0.5U of T4 ligase 
(NEB). Ligation was carried for 2 hr at room temperature. 
3.2.5.5 Transformation 
I 
20|xL of the ligation products were added to 50|iL of competent cells (DH5a 
Escherichia, coli competent cells) (Invitrogen) and put on ice for 15 min. The mixture 
was subjected to heat-shock procedures (42°C for 90 sec; 4°C for 3 min), following by 
� incubation with 200|iL of SOC medium (Invitrogen) for Ihr a 37°C. After the 
incubation, the mixture was spread onto agar plates containing lOOmg/mL of ampicillin 
(USB Corporation) and incubated at 37°C overnight for colony formation. 
3.2.5.6 Preparation of the Cloned Plasmid 
Single bacterial clones were picked and inoculated overnight at 37°C with 
vigorous shaking in lOOmL of LB broth (Invitrogen) to prepare for purification on the 
next day. Purification of plasmid was performed using the DNA-midi™ Plasmid 
DNA Purification Kit (TechDragon Ltd.) according to the manufacturer's protocol. In 
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brief，bacterial cells were harvested by centrifugation at 13,000 rpm for 5 min at 4°C. 
The bacterial pellet was re-suspended in 3 mL of Ml buffer, 3 rtiL of M2 buffer for 5 
min, and 4.2mL of M3 buffer for 15 min on ice. After the incubation, the mixture was 
centrifuged at 13,000 rpm for 10 min at 4°C, and the supernatant was transferred to 
500|xL of midi-Bead solution. Through centrifugation at 13,000 rpm, a midi-bead 
pellet was obtained. The pellet was washed with 700iaL of Washing buffer A before 
transferring to the filter column. After spinning down the column, 700|xL of Washing 
buffer B was added and the spin-down was repeated. The sample was finally eluted 
with 300|xL ofElution buffer. 
3.2.5.7 Sequencing of the Cloned Plasmid 
The purified plasmid was subjected to sequencing analysis for verification of the 
3'UTR sequence cloned into the pMIR expression vector. 50ng/|iL of the purified 
plasmid was sent to TechDragon Ltd. for sequencing analysis using the pMIR FW 
primer (5'- AGGCGATTAAGTTGGGTA-3'). 
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3.2.6 Site-Directed Mutagenesis 
Seed regions were mutated to remove complementarity to the miRNA seed region 
by using the QuickChange® II Site-Directed Mutagenesis Kit (Stratagene) according to 
the manufacturer's protocol. The mutation primers and the mutation sites are listed in 
Table 3.4. In brief，l|ig of the wild-type 3'UTR cloned pMIR vector (ZNFXl-pMIR/ 
DNAJB12-pMIR) was subjected to PGR amplification in a total of 25|iL reaction 
volume (Ix reaction buffer; 10|iM of each forward and reverse primer; 0.5|xL of the 
I 
dNTP mix; 0.5|iL of PfuUltrall FusionHS). The thermal profile was as follows: 95°C 
for 2 min; 25 cycles of 95°C for 30 sec, 50�C for 30 sec, 72�C for 3 min; 72�C for 7 min, 
and finally terminated at 4°C. The PGR amplified plasmids were subjected to Dpnl 
(Stratagene) digestion for 5 hrs at 37�C. Following the digestion with Dpnl, the 
plasmids were transformed, purified, and sequenced in procedures similar to section 
3.2.5.5 to section 3.2.5.7. 
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Table 3.4 Primers for site-directed mutagenesis 
Target Genes P r imer Sequence (5，->3，) microRNA Target Site 
R1 CGC CTG TAA TCC CAG GTG TTT GGG AGG Poorly conserved region at 
CCGAGG position 134-140 
i 諭 _ 寵 _ _ _ _ 穩 漏 _ 讓 . 
R2 TAG CCC TGC GCT AGA GTA AGG TGT TTA Conserved region at 
‘ TCT CCA GAA CTG AGA G position 483-491 
_ _ i l i “ T C ; r ( ? A G r r p T G M G A I A A A C A C C T T ^ , 1 
i l l i i i i i l ^ 
R1R2 Same as above Double mutation at both 
R1 & R 2 
p p p i i l K i l i a i i i i i i i i i i i ^ 
CTC AGT TCT GGA GAT A TA CTC TAG 
CGC AGG GG 
R1 CCT AGA CGG GCT GAG CCA TGT CGT ATA Conserved region at 
AGAACATAGATC CTAAAG position 2876-2883 
| ^ _ _ 讓 _ _ 國 _ _ 画 羅 | 
《：：； . ^ . T G G C T C A G C C C G T C T A G G - > • ‘ ： ： 
** The bold nucleotides were the mutated sites where C replaces G, while A replaces T and vice versa. 
Dashes indicate deletion of nucleotides. 
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3.2.7 Dual-Luciferase Assay 
Dual-Luciferase Assay (Promega, Madison) was performed at 24hr 
post-transfection. To measure the firefly/renilla signals, cells were harvested and 
washed with Ix PBS. 100|iL/well of Ix Passive Lysis Buffer (Firefly & Renilla 
Luciferase Assay Kit, Biotium, Inc.) was added the 24-well culture plate and incubated 
for 15 min on shaking platforms. Then the lysates were transferred to 
micro-centrifuge tubes ready for the dual-luciferase assay. 50|aL of LARII reagent 
I 
(Promega, Madison) was added to 20|iL of sample lysates, and the luminescence for the 
firefly signal was measured over a period of 10 seconds. Then 50|xL of STOP & GLO 
reagent (Promega, Madison) was added to the mixture, and luminescence for the renilla 
signal was measured. Luminescence was integrated over a period of 10 seconds. 
3.2.8 Western Blot Analysis 
To investigate the effect of inhibiting miR-106b, miR-93, and miR-25 on the 
protein levels in DAOY, western blotting analysis was performed using protein lysates 
that were collected 24hr post-transfection of microRNA inhibitors. Cells were first 
washed with Ix PBS. Protein lysates were coilected by adding 800^iL/well of 
Nonidet-P40 (NP40) buffer (150mM sodium chloride, 1% NP-40, 50mM Tris, pH8.0) 
supplemented with lOmM NaF, ImM of Na Orthovanadate, and ImM of PMSF. The 
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concentrations of the protein lysates were determined using the Bio-Rad Protein Assay 
(Bio-Rad) according to the standard protocol. Proteins from each lysates (40|ig) were 
separated on 12.5% SDS-PAGE gel and transferred onto nitrocellulose membrane. 
The nitrocellulose membrane was incubated in blocking buffer (6% non-fat milk) for 
Ihr at room temperature. Following the incubation, it was incubated with primary 
antibodies: mouse polyclonal to ZNFXl antibody (1:1000) (ab69172，abeam), or rabbit 
polyclonal to p-actin antibody (1:10,000) (ablSOl, abeam) overnight at 4°C. After 
several washes with IxPBS-Tween (IxPBS with 20% Tween), the membranes were 
separately incubated with secondary antibodies: goat polyclonal secondary antibody 
(1:5,000) to mouse IgG-HRP (abeam) for ZNFXl, and goat polyclonal secondary 
� antibody (1:5，000) to rabbit IgG-HRP (abeam) for P-actin. The bound antibodies were 
visualized by using the ECL plus™ detection kit (GE Healthcare). The 
chemiluminescence signals were captured by Kodak XAR-5 film at various exposure 
times depending on the different antibodies used. 
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3.3 Results 
**A11 statistical comparisons are based on Student Mest, where negative controls refer 
to treatment with anti-miR negative control#l (Ambion). 
3.3.1 Expression Levels of miR-106b-25 cluster in MB Cell Lines 
The expression profiles of the selected miR-106b-25 cluster were determined by 
real-time stem loop PGR amplification in seven MB cell lines (ONS-76, DAOY, D425, 
D458，D384, D341 Med, and D283 Med) and in five normal cerebellum samples (4 
J 
adult & 1 fetal). The profile showed that miR-106b-25 cluster exhibit different degree 
of increase for most of the MB cell lines compared to the average of the normal 
cerebellum (Figure 3.2). Of the 7 MB cell lines, ONS-76 and DAOY showed 
� distinctive increase in miR-106b (8.4-fold, 8.3-fold), miR-93 (14.3-fold, 21.8-fold), 
and miR-25 (12.5-fold, 10-fold) respectively in the two cell lines. 
A 
Taqman Stemloop qRT PCR (miR-106b) 
o 10.00 
I I 8.。0 I I 
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B 
Taqman Stemloop qRT PCR (miR-93) 
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Taqman Stemloop qRT PCR (miR-25) 
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Figure 3.2 Taqman stemloop qRT PCR analyses of miRNA expression levels in MB 
cell lines and normal cerebellum. 
Taqman Stem-loop qRT PCR analyses indicated general trend of up-regulation for this 
cluster of microRNA in most of the MB cell lines. (A) miR-106b is up-regulated in 
ONS-76，DAOY, D425，D341 Med, and D283 Med. (B) miR-93 is up-regulated in all 
cell lines examined. (C) miR-25 is up-regulated in ONS-76, DAOY, D425, D341 Med, 
and D283 Med. Data shown are expressed as relative miRNA expression level 士SD. 
Dotted lines denote the value of the average of cerebellum samples. 
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3.3.2 Evaluation of Transfection Efficiency Using Lipofetamine2000 
Transfection efficiency using Lipofectamine 2000 was tested using the 
FITC-labeled double stranded RNA (BLOCK-iT Fluorescent Oligo). The transfection 
efficiency was determined by the ratio of FITC-positive cells/ total cell numbers. It 
was observed that the transfection efficiency achieved -70% using the recommended 
reagent concentrations suggested by the manufacturers (Figure 3.3). 
I 
A B 
• H H 
Figure 3.3 Transfection efficiency using Lipofectamine 2000. 
Representative images of DAOY cells transfected with FITC-labeled double stranded 
oligo. FITC signal was examined under a fluorescence microscope at 24hr 
post-transfection. (A) DAOY cells captured in bright field, while (B) indicates the 
same area captured using the fluorescence field. 
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3.3.3 Blocking Efficiency of MicroRNA Inhibitors 
The efficiencies for blocking endogenous microRNAs (miR-106b/miR-93 
/miR-25) using specific microRNA inhibitors were examined using Dual-luciferase 
assay. Anti-sense inhibitors of miR-106b (anti-miR-106b)，miR-93 (anti-miR-93), 
and miR-25 (anti-miR-25) were employed to block the activities of their respective 
endogenous microRNAs. The microRNA inhibitors were co-transfected with a 
pMIR-REPORT™ vectors that were cloned with the complementaiy sequence of the 
I 
corresponding microRNA. Restoration of luciferase activity resulted from inhibiting 
the endogenous microRNA from targeting the complementary sequence of the reporter 
construct was observed in all three microRNAs (Figure 3.4). Specifically, luciferase 
activity was increase after treatment with anti-miR-106b, anti-miR-93, and 
anti-miR-25 for �2.2-fold，~2.0-fold, and �1.4-fold respectively in DAOY (Figure 3.4). 
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Figure 3.4 Inhibitory effect of anti-miRNAs. 
Dual-luciferase assay was used to examine the blocking efficiency of specific 
microRNA inhibitors with specific complementary sequence of miRNA cloned in the 
luciferase reporter construct in DAOY. The % of Luciferase activities were 
normalized with their respective Renilla activities, then compared to the control 
without treatment with miRNA inhibitors. Data shown are expressed as normalized 
firefly to renilla relative to the control 士SD. (n=3) 
3.3.4 Target Prediction List 
Different target prediction programs resulted in different number of predicted 
target genes for a given microRNA as summarized in Table 3.5. The number of 
predicted target genes varied from hundreds to several thousands. Among the 
predicted target genes, ones that were found common in all seven prediction programs 
are listed in Table 3.6. 
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Table 3.5 Number of predicted target genes from different prediction programs 
hsa-iniR-106b predicted targets 
E S 瞧 I 薩 a i ^ K • 纖 • 麵 麵 g 經 二 二 ] 
miRanda 178 
i i i l i l i i S ^ i ^ Z S Z i i l S l l l S S f E I Z I I ] 
Pic Tar 726 
i i S i i l l i i ^ i l E I l l i l i l E l l M S S S E a 
EIMMo2 5280 
miRDB ' m 
J 
hsa-miR"93 predicted targets 
• PredictionProgra^s^^ !!：^^. f •〈婉m—fP^e—dicted Targets … . ‘ < 
miRanda 473 
Pic Tar 613 
_驅 2 7 1 」了：了蘼二:riJSIESESi:: 
EIMMo2 5706 
i «f t» > AKW ^ ^ i ^ t J/ nd t riuhib ^ ^ J- ^ ^ ^ ^ ^ 1 
miRDB m 
hsa-miR-25 predicted targets 
miRanda 192 
i ^ B i g i ^ ^ i i i l i E i l i 誕 觀 




Table 3.6 Common predicted targets among the seven prediction programs 
hsa-miR-106b common hsa-miR-93 common hsa-miR-25 common 
predicted targets predicted targets predicted targets 
I K i i ^ ^ B i l i i i M i l l i g i i l l l E I Z ] 
MAP3K9 MYCN JOSDl 
H M l i i ^ M l l l S i E l M l 麗:IZ] 
NR4A3 TUSC2 SLC17A6 
iliffiiliiili^il^^^EilinsZEI] 
PTPN4 ZNF512B 




3.3.5 Recognition Sites of Potential Targets 
� ZNFXl was predicted to harbor miR-106 and miR-93 recognition sites in its 
3'untraslated region (3'UTR); therefore, it was chosen to act as a study model for both 
miR-106b and miR-93. Of the recognition sites for miR-106b，there were two 
conserved regions and two poorly conserved regions. For miR-93, there is one 
conserved and one poorly conserved region; in addition, they share the same 
recognition sites with miR-106b. The specific location of these recognition sites were 
summarized in Table 3.2 in the Materials and Methods section. On the other hand, 
DNAJB12 was chosen to act as a study model for miR-25, and its potential miR-25 
recognition site locates at 2876-2883bp on its 3'UTR (Table 3.2). 
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3.3.6 Expression Levels of ZNFXl in MB Cell Lines 
The mRNA expression level of ZNFXl was examined in ONS-76 and DAOY by 
qRT-PCR. Relatively lower expression of the mRNA level of ZNFX 1 was observed in 
both cell lines as compared to the normal cerebellum (Figure 3.5). The 
down-regulation of mRNA level of ZNFXl in cell lines is in line with the known 
up-regulation of the miR-106b, and miR-93. 
ZNFXl 
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Figure 3.5 Quantitative real-time PGR for candidate genes. 
Shown in the figure is the relative mRNA expression level of ZNFXl compared to the 
average of normal cerebellum samples expression 士SD. Each expression levels were 
normalized with the reference gene (RPS3). (n=3) 
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3.3.7 Transcriptional Regulation of ZNFXl and DNAJB12 
Recall that microRNAs can regulate their target(s) through both transcriptional 
and translational regulations, therefore, mRNA level of ZNFXl and DNAJB12 were 
examined using qRT-PCR in DAOY cells. Statistical analysis suggested that there 
were distinctive up-regulation of mRNA transcript levels in ZNFXl upon treatment 
with anti-miR-106b, and anti-miR-93 inhibitors (Figure 3.6A). On the other hand, 
distinctive up-regulation of mRNA transcript level in DNAJB12 was also observed 
I 
when cells were treated with anti-miR-25 as marked by the asterisks in Figure 3.6B. 
Therefore, ZNFXl was chosen to be the study model for miR-106b and miR-93 as it is 
a common target predicted by the programs to be regulated by these two microRNAs, 
and that it is transcriptionally regulated by miR-106b and miR-93. While DNAJB12 
was chosen to act as the study model for miR-25, because among the common targets 
predicted for miR-25 (data not shown), DNAJB12 was the only that was regulated by 
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Figure 3.6 Changes in target gene expression in DAOY. 
Quantitative real-time PGR was used to examine the temporal changes of mRNA 
transcripts of ZFNXl (Fig 3.6A), and DNAJB12 (Fig 3.6B) upon treatment with 
anti-miRNA inhibitors. Data shown are expressed as relative mRNA to reference gene 
expression 士SD. (n=3) **denote p<0.05 
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3.3.8 Verification of Potential Target Genes 
To further verify whether ZNFXl and DNAJB 12 are target genes regulated by the 
miR-106b-25 cluster, dual-luciferase assay was performed. Luciferase expression 
vector cloned with the 3'UTR of the two potential target genes (ZNFXl-pMIR & 
DNAJB 12-pMIR) were co-transfected along with specific microRNA inhibitors into 
DAOY, and luciferase activities were examined 24-hr post-transfection. Treatment 
with anti-miR-106b and anti-miR-93 (but not anti-miR-25) could specifically release 
I 
the endogenous microRNA suppression on the 3'UTR of ZNFXl, which led to the 
increase in luciferase activity (marked by the asterisks in Figure 3.7A). On the other 
hand, treatment with anti-miR-25 also released the endogenous miR-25 suppression on 
the 3'UTR of DNAJB 12, leading to an increase in luciferase activity (marked by the 
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Figure 3.7 Relative luciferase activity ofpMIR-ZNFXl and pMIR-DNAJB12 
(A) The levels of luciferase activity of ZNFXl-3'UTR-cloned pMIR after treatment 
with anti-miR-106b, anti-miR-93, and anti-miR-25 inhibitors are indicated in the 
histograms (**p<0.00 for both anti-miR-106b & anti-miR-93). The SD for 
anti-miR-106b, anti-miR-93, anti-miR-25, negative control, and mock are �0 .4 ’ -0.2, 
�0.3，�0.2，and -0.1 respectively. (n=3) (B) The levels of luciferase activity of 
DNAJB12-3'UTR-cloned pMIR after treatment with anti-miR-25 show a significant 
increase (**p<0.04). The firefly signals were normalized to the corresponding Renilla 
signals. Relative luciferase activities were expressed as the ratio of the normalized 
activity of the treated cells to the negative control. (n=3) 
60 
3.3.9 Identification of Critical Target Sites 
To narrow down the critical target site(s) recognized by the specific microRNAs, 
we have induced site-directed mutagenesis at various predicted target regions on the 
3'UTR of ZNFXl，and DNAJB12. The constructs with the mutated regions for 
ZNFXl are shown in Figure 3.8A. Let's consider the expected results for the 
wild-type construct. Under the negative control condition (without treatment of 
miRNA inhibitors), endogenous miRNAs would bind onto the miRNA recognition sites 
I 
on the wild-type 3'UTR leading to a suppression of luciferase activity. Now, consider 
the same wild-type construct upon treatment with miRNA inhibitors. Because the 
endogenous miRNAs are inhibited, the suppressions caused by the endogenous 
miRNAs are now relieved; therefore, leading to an increase in luciferase activity 
relative to its negative control. As a result, we should expect to see a significant 
increase for the change in luciferase activity between the treated sample and its 
negative control for the wild-type construct. On the other hand, consider the case for 
the mutated construct. Under the negative control condition, endogenous miRNA 
would not be able to bind onto the miRNA recognition site due to the induced mutation, 
thus luciferase activity is not suppressed. Upon treatment with miRNA inhibitors for 
the same mutated construct, similar luciferase activity is expected because endogenous 
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miRNAs could not bind on to the mutated miRNA recognition site regardless of the 
treatment with miRNA inhibitors. As a result, we should expect either minimal or no 
change in luciferase activity between the treated sample and its negative control for the 
mutated construct. From our data, the wild-type ZNFXl 3'UTR, as expected, showed 
an increase in luciferase activity upon treatment with anti-miR-106b, and anti-miR-93 
inhibitors. The relative change in the percentage of luciferase activity reached � 5 5 % 
for anti-miR-106b, and ~56% for anti-miR-93 compared to the negative control (Figure ‘ 
丨 3.9A), suggesting that it carries the potential target sites for the two miRNAs. 
Mutation at the poorly conserved recognition site (Rl) showed similar change in 
relative luciferase activity as the wild-type construct (~58% for anti-miR-106b, and 
� � 5 7 % for anti-miR-93) (Figure 3.9A), indicating that Rl do not carry the critical 
miRNA recognition site. Mutation at R2 resulted a decrease in change of relative 
luciferase activity (~31% for anti-miR-106b, and � 2 9 % for anti-miR-93) (asterisks in 
Figure 3.9A), which indicate that R2 contains the critical recognition site for both 
miR-106b and miR-93. Subsequent double mutation at both target sites (R1R2), and 
total deletion of the seed region at R2 (Del-R2) both showed similar decrease in the 
change in relative luciferase activity as the single mutation at R2 (Figure 3.9A), which 
further confirms the importance of R2 for the specific microRNA suppressions. The 
consistent decrease in change in relative luciferase activity observed for R2, R1R2, and 
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Del-R2 constructs demonstrated that R2 is the critical miRNA recognition site for 
miR-106b and miR-93. When R2 is mutated, regardless whether the microRNA 
inhibitors or the random oligonucleotides (negative control) were added, the change in 
relative luciferase activity was minimal as compare to the change observed for the 
wild-type construct. 
The mutation construct for the 3'UTR of DNAJB 12 is depicted in Figure 3.7B. 
For the wild-type DNAJB 12 3'UTR, as expected, there was an increase of-14% in the ‘ 
‘ luciferase activity upon treatment with anti-miR-25 inhibitor compared to the negative 
control (Figure 3.9B). This suggests that the 3'UTR of DNAJB 12 carries the miR-25 
recognition site(s). However, mutation at the conserved region (Rl) showed a similar 
, increase of ~10% in luciferase activity as the wild-type construct (Figure 3.9B). This 
suggests that Rl may not be the critical miRNA recognition site for miR-25. The 
critical recognition site(s) for miR-25 remain to be determined. 
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Figure 3.8 Luciferase constructs with mutations at microRNA target sites. 
Shown in (A) are the luciferase constructs carrying specific mutations for ZNFXl， 
while shown in (B) are the luciferase constructs for DNAJB12. 
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Figure 3.9 Site-directed mutagenesis of 3'UTR. 
Relative luciferase activity of (A) ZNFXl-pMIR, and (B) DNAJB12-pMIR harboring 
various specific mutation(s). Specific expression vector was co-transfected along with 
miRNA inhibitors (anti-miR-106b/miR93/miR25) in DAOY. The luciferase activities 
were normalized with Renilla, and compared to their relative negative controls 士SD. 
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3.3.10 Effects of Anti-microRNA Inhibitor on ZNFXl Protein Levels 
Considering ZNFXl as a promising target of miR-106b and miR-93, western blot 
analysis was performed to test whether the protein levels fluctuate upon inhibiting 
miR-106b and miR-93. It was observed that anti-miR-106b and anti-miR-93 
increased ZNFXl protein level (Figure 3.10), consistent with ZNFXl being their direct 
target. Together with the real-time data, it is likely that miR-106b and miR-93 exhibit 
post-transcriptional regulation on ZNFXl. 
I 
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Figure 3.10 Western Blotting of ZNFXl. 
There was a general trend of increase in ZNFXl protein levels when miR-106b, 
miR-93, and miR-25 were inhibited in DAOY. Shown is the Western blot with 
anti-ZNFXl and anti-actin antibodies, p-actin was used as a loading control. 
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3.4 Discussion 
Increasing data support the value of microRNA expression profiling to unravel the 
role of microRNA in contributing to the pathogenesis of different human malignancies. 
In a study conducted previously by our group, up-regulation of the miR-106b-25 cluster 
was observed in primary MB samples compared to the normal cerebellum samples. 
The up-regulation of this cluster of microRNA was also reported in Ferretti et al. ’s 
microRNA profiling study in human medulloblastoma (Ferretti et al. 2009). Thus, it 
I 
raises the possibility that the differential expression of this cluster of microRNA may be 
linked to the oncogenic properties of MB. Focusing on the miR-106b-25 cluster, the 
expression of this cluster was further examined in seven MB cell lines. Stem-loop 
qRT-PCR amplification revealed that this cluster of microRNA is differentially 
expressed in different MB cell lines, and with remarkable up-regulation in ONS-76 and 
DAOY. With these preliminary data, our main goal in this chapter was to identify 
target genes regulated by miR-106b-25 cluster using the computational approach. By 
employing seven target prediction algorithms, altogether �75,000 potential target genes 
were generated for this cluster of microRNA (Table 3.5). By combining the seven 
prediction lists and selecting only the common ones, we were able to successfully cut 
down the number of potential target gene to ten or less (Table 3.6). Although 
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microRNAs are known to regulate their targets mainly through translational repression, 
others have also reported that they achieve silencing of cellular messages through 
mRNA cleavage (Li et al. 2009). Therefore, as a preliminary screen for transcriptional 
regulation, qRT-PCR was used to examine the effects of inhibiting the miR-106b-25 
cluster on the selected potential target genes (ZNFXl as the potential target gene for 
miR-106b & miR-93, while DNAJB12 as the potential target gene for miR-25). From 
the qRT-PCR analysis of ZNFXl mRNA expression level in DAOY, it was found that ‘ 
‘ upon inhibition of miR-106b and miR-93, the mRNA level of ZNFXl was increased 
(Figure 3.6A). Similar result was also observed for the DNAJB12 mRNA expression 
level when miR-25 was inhibited (Figure 3.6B). These data suggest the presence of 
,, miRNA: target mRNA interactions. For further verification using in-vitro models, 
luciferase reporter assay was carried out to determine if there was direct interaction of 
miR-106b and miR-93 at the 3'UTR of ZNFXl, as well as miR-25 at the 3'UTR of 
DNAJB 12. Upon treatment with anti-miR-106b and anti-miR-93, there was 
significant increase in luciferase activity observed for ZNFXl (Figure 3.7A). 
Similarly, upon miR-25 inhibition, there was also a statistically significant increase in 
luciferase activity observed for DNAJB 12 (Figure 3.7B). These data suggest that their 
3'UTRs exert direct interactions with the miR-106b-25 cluster. Consistently, the 
increase in luciferase activity was only observed in specific microRNA that was chosen 
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for its own model. For instance, ZNFXl was predicted as the target gene for 
miR-106b and miR-93 only, increase in luciferase activity was only observed when 
miR-106b and miR-93 were inhibited, but not for miR-25. Similarly for DNAJB 12, 
which was predicted to be a target gene for miR-25, significant increase in luciferase 
activity was observed only when miR-25 was inhibited. These data suggest that 
miRNA:mRNA interactions are indeed very specific, and that subtle differences 
between homologue microRNA may have meaningfully purpose leading to different ’ 
‘ functional importance (Petrocca et al. 2008). In an effort to narrow down the specific 
recognition site(s) on the 3'UTR, site-directed mutagenesis was used to induce 
mutation on the predicted target sites. There were two conserved regions and two 
, poorly conserved regions for miR-106b, while there was only one conserved region and 
one poorly conserved region predicted for miR-93 (Table 3.2). The two predicted 
target regions for miR-93 (both conserved (R2) and poorly conserved (Rl)) share the 
same locations on the 3'UTR of ZNFXl as miR-106b; therefore, they were chosen for 
site-directed mutagenesis study. Of the two regions examined, only the conserved 
region at 484仇-491 (R2) resulted in a decrease in the relative change in luciferase 
activity, while mutation on the poorly conserved region showed similar change in 
relative luciferase activity as compared to the change observed for the wild-type 
construct (Figure 3.9). This observation re-enforces the idea that microRNAs are 
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normally highly conserved in the genomes of related species (Yoon and De Micheli 
2006), and perhaps more emphasis may be put onto testing conserved regions prior to 
testing poorly conserved regions when performing verification tests. Also, double 
mutation at both target sites (R1R2) showed a similar decrease in the change in relative 
luciferase activity as the single mutation at the conserved site (R2), which again 
showed that the poorly conserved site have little contribution in miR-106b and miR-93 
target regulation. Deletion of the entire seed region at the conserved site (Pel-R2) ‘ 
‘ showed further decrease in the change in luciferase activity as compared to mutating 
only three consecutive nucleotides at the seed region (R2). This observation suggests 
that complementarity has significant impact on microRNA regulation and that the 
degree in complementarity is directly related to the degree of regulation. As proposed 
in section 3.3.9，if the mutated region were the true critical recognition site for the 
specific miRNA, we would expect no change or very minimal change in the relative 
luciferase activity between the treatment with inhibitors and its negative control 
because the suppression effects of endogenous miRNAs on the recognition site(s) were 
abolished by the induced mutation. However, in our ZNFXl model, although the 
change in relative luciferase activity for the R2 mutated constructs was clearly reduced 
by approximately half fold compared to the change observed for the wild-type 
construct, but it was not as ideally expected to be totally abolished. This observation 
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could be explained by the fact that R2 is only one of the critical recognition sites 
targeted by miR-106b and miR-93 on the 3'UTR of ZNFXl. Another critical 
recognition site may exist along the 3'UTR of ZNFXl; therefore, when endogenous 
miRNAs were inhibited using miRNA inhibitors, the miRNA suppression at this 
unknown recognition site was relieved. As a consequence, the change in relative 
luciferase activity was not totally abolished. In fact, there are still one conserved 
region (located at 1324"^ -1331®*), and one poorly conserved region (located at 
‘ 979th-985th) on the 3'UTR of ZNFXl predicted by TargetScan 4.2 remained to be 
verified. Now, let's consider the other predicted target gene, DNAJB12. Previous 
luciferase reporter assay had demonstrated a significant increase in luciferase activity 
� for DNAJB12 upon inhibition of miR-25. However, site-directed mutagenesis at the 
predicted conserved region resulted in similar change in relative luciferase activity as 
the wild-type construct (Figure 3.9B). In other words, mutation at this site has no 
effect on the regulation mediated by miR-25, and thus not a critical recognition site for 
miR-25. There is still hope that somewhere along the 3'UTR of DNAJB12 may 
harbor a target site for miR-25; however, it is definite that this particular region is a 
false positive indicating that there are potential flaws embedded in the prediction 
programs. It is still too early to tell whether DNAJB12 is truly a false positive, but 
discouragingly we are back to the trial and error stage. Shifting back our focus on 
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ZNFXl, because microRNAs function to regulate gene expression at the 
post-transcriptional level (Olive et al. 2010)，western blot analysis was performed to 
examine the protein level of ZNFXl upon inhibition of miR-106b, miR-93，and miR-25. 
It was observed that upon treatment with anti-miRNA inhibitors (anti-miR-106b， 
anti-miR-93，and anti-miR-25) the protein level for ZNFXl was increased. The slight 
increase in protein level observed for treatment with anti-miR-25 along with the two 
other treatments may be due to the fact that this cluster of microRNA works in a ‘ 
‘ cooperative manner, affecting other factors that might exert an indirect feedback on 
miR-25. However, whether the observed increase in protein level is purely through 
post-transcriptional miRNA regulation or a combination with translational regulation 
. � still remain to be determined. Taken altogether, we determined that ZNFX1 is a target 
regulated by miR-106b and miR-93 in MB. NFXl-type zinc finger-containing protein 
1 (ZNFXl) is located on chromosome 20ql3.13. It is conserved in dog, cow, mouse, 
rat, chicken, fruit fly, and mosquito (Ashbumer et al. 2000). ZNFXl is not commonly 
studied in human; therefore, its exact function is still unknown. However, it is 
proposed to interact selectively and non-covalently with metal ions (Ashburner et al. 
2000). In a study of Atlantic cod conducted by Rise et al., the transcript level of 
ZNFXl was found to be upregulated by more than 10 fold in Atlantic cod with high 
nodavirus carrier state (Rise et al. 2010). Nodavirus is found to target nervous tissue 
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causing viral nervous necrosis that leads to neurological damage, swimming 
abnormalities, and morbidity in aquacultures (Rise et al. 2010). This observation 
suggests that ZNFXl may be involved in the contribution of nervous necrosis 
associated with Nodavirus. Although Rise et al. used Atlantic cods as their study 
model, it is possible that ZNFXl may be linked to brain abnormality in human too. As 
a future direction, using MB as a model may help to elucidate the functions of ZNFXl 
and its link to human brain diseases. 
In this chapter, we see that computational approaches for most time rely on few 
established principles when predicting targets, such principles include recognition 
patterns, number of complementarity, and degree of conservation between species etc... 
� However, it cannot reveal novel aspects of microRNA target recognition (Orom and 
Lund 2010)，and despite false positives, it gives no information on false negative targets. 
Nevertheless, it forms a basic framework and generates lists of putative targets for 
researchers to start with. 
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CHAPTER 4:- EXPERIMENTAL APPROACH IN INDENTIFYING 
POTENTIAL TARGETS 
4.1 Introduction- Experimental Approach 
As discussed in the previous chapter, identification of microRNA targets using the 
computational approach proves to be challenging because prediction programs are 
usually based on a few of the established principles of microRNA regulatory 
mechanisms, namely, the idea of complementarity. However, microRNAs and their 
targets often form "imperfect" base-pairing with each other, especially in animals. 
Therefore, many researchers use the experimental approach to identify potential targets 
for microRNAs. A number of different experimental approaches are available; some 
� , of the commonly used ones are transcriptome analyses, immunoprecipitation of RISC 
complex, and polysomal distribution analyses (Orom and Lund 2010). 
Transcriptome analysis involves examining the shift in mRNA expression profile 
using microarrays (Lim et al. 2005). As a consequence of over-expressing or 
inhibiting specific microRNAs, a large set of microRNA targets can be identified (Lim 
et al. 2005). Although the microarray approach allows one to analyze a large set of 
target genes at the same time, it is limited to target genes that are regulated at the 
transcriptional level (Orom and Lund 2010). It gives no information on target genes 
that are regulated primarily at the translational level. 
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Perhaps immunoprecipitation of tagged RISC complex may be a better approach to 
investigate target genes that are translationally regulated by microRNAs. As 
mentioned before, mature microRNAs are incorporated into RISC, and bound by 
members of the Argonaute (Ago) family to mediate their regulatory effect as a complex 
(Karginov et al. 2007). Several reports support the identification of miRNA targets by 
immunoprecipitating either the tagged or endogenously expressed Ago proteins to 
analyze the associated mRNAs of specific microRNA. Through subsequent analyses 
‘ of the immunoprecipitates using the microarrays, targets that are regulated at both the 
transcriptional and translational level could be identified (Karginov et al. 2007). 
It has been reported that microRNA targets exhibit change in the polysomal 
.. distribution (Nelson et al. 2004)，as such potential targets can be identified by 
over-expressing or inhibiting specific microRNAs followed by subsequent analyses of 
their polysomal spectrum and associated mRNA using micro-arrays (Nelson et al. 
2004). Assuming that a transcript's position in the polysome profile somewhat reflects 
the degree of its translation and that, shifts into the heavier polysome fraction reflect 
enhancement of translation, Nakamoto et al. had successfully identified mRNAs that 
were regulated by specific endogenous miRNA by analyzing the difference in mRNA 
abundance in the polysome profile followed by miRNA knockdown (Nakamoto et al. 
2005). More specifically, they found that the mRNA levels of several genes, such as 
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CYR61 and CDK6 were significantly increased in the heavy polysome fractions 
following miR-30a-3p knockdown (Nakamoto et al. 2005). Subsequent analysis of 
the identified transcripts revealed partial complementarity to miR-30a-3p, yet none of 
the identified transcripts were predicted by commonly used computational programs 
(Nakamoto et al. 2005). Their data again re-enforce the importance of experimental 
approaches in identifying miRNA target genes. 
As described, there are several ways to identify miRNA targets experimentally, in 
‘ this chapter we have employed a biochemical method to identify potential target genes 
that are regulated by the miR-106b-25 cluster. Using C. elegans as a study model, 
Andachi had developed a novel method to identify target genes regulated by specific 
� microRNAs by isolating cDNA clones of mRNAs that formed base pairs with the 
microRNA of interest (Andachi 2008). C. elegans is the most intensively studied 
organism in the field of microRNA research with more than 150 microRNAs identified 
(Andachi 2008). Using this method, Andachi had successfully isolated cDNA clones 
of lin-4 and its known target gene lin-,14, as well as identified and confirmed new target 
for let-7 (Andachi 2008). Adapting from Andachi's method, we aim at identifying 
target genes regulated by specific microRNA of interest in human cells, specifically in 
MB cells. The goal is to isolate a library of cDNA clones that contain partial sequence 
of potential target genes for miR-106b in DAOY. The schematic of the method is 
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shown in Figure 4.1. The method relies on the base pairing regulatory mechanism of 
miRNAs and their targets, which allows endogenous miRNAs to act as primers in the 
reverse-transcription reaction to synthesize cDNAs that contain partial sequence of the 
target genes. Then, through series of specific enzymatic digestion and ligation to 
pre-designed adaptors, sequences specific to the miRNA of interest can be amplified 
and inserted into pCR2.1 vectors creating a library of cDNA clones. Subsequent 
sequencing of the vectors would reveal partial sequence that shows homology to ‘ 
‘ mRNA transcripts, which may be potential targets of the given miRNA. 
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Figure 4.1 Schematic diagram of the biochemical method. 
(1) Under normal physiological condition, miRNAs are incorporated into RISC. 
Together as a complex, it binds onto the mRNA of its target. (2) The endogenously 
expressed miRNAs would act primers to initiate reverse transcription, enabling the 
synthesis of first-strand cDNA complementary to the target gene sequence. (3) 
Amplification of the target gene sequence using the specially designed Adaptor and 
a miRNA primer labeled with biotin would selectively amplify the desired sequence 
for the miRNA of interest. (4) Using restriction enzyme digestions, the sequences 




4.2.1 Isolation of cDNA Clone Library 
The detailed schematic diagram of the method is shown in Figure 4.1 • The step by step 
description of the procedures will be described in the sections that follow (4.2.1.1 to 
4.2.1.15). 
4.2.1.1 Preparation of Cytoplasmic Extracts 
DAOY cells were cultured in 100mm plates, and harvested at 60% confluence in 
order to obtain cells that were actively growing and involved in protein synthesis. 
Cells were washed with ice-cold IxPBS and trypsinized for cell count. All 
centrifugations from here on in this section were kept at 4°C. Approximately 1x10^ 
cells were centrifuged at 1000 rpm for 3 min to obtain the cell pellet. After removing 
the supernatant, the cell pellet was re-suspended in 10 vol of ice-cold cell fractionation 
buffer (PARIS™ Kit, Ambion). The cell extract was incubated on ice for 5 min, and 
centrifuged at 500g for 3 min to separate the nuclear and the cytoplasmic cell fractions. 
While avoiding the nuclear pellet, the supernatant was collected and centrifuged at 
13,000rpm for 5 min to precipitate cell debris and the nuclei. The supernatant was 
mixed with 0.1 vol of 10% (w/v) SDS, and incubated on ice for 1 min. The short-term 
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treatment with SDS at low temperature was included to destabilize the RISC as it may 
reduce the efficiency of the reverse transcriptase and the efficiency of miRNA priming. 
The general procedures in this section are depicted in Figure 4.2. 
乂Vhole Cell I t l ^ ^ S D S 
I > , I ；> ‘ 
了一 I.::,, yDSupematant ^ Cytoplasmic Extract 
^^isrupt RISC 
mRNA of target gene 
Figure 4.2 Preparation of cell extracts. 
DAOY cells were collected using PARIS™ Kit. The cytoplasmic fraction was 
subjected to SDS treatment to disrupt the RISC complex. 
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4.2.1.2 Reverse Transcription Using Endogenous miRNA as Primers 
After the short-term treatment with detergent, the reaction mixture was 
immediately diluted to 200 vol using “ 1 ®^-round"-reverse-transcription buffer. The 
components of the “ 1 ®^-round"-reverse-transcription buffer are listed in Table 4.1. In 
this reverse transcription reaction, endogenous miRNAs would act as primers to 
synthesize first-strand cDNA (Figure 4.3) The reaction mixture was gradually raised 
from 4°C to 37°C in lOmin, and kept at 37°C for 1 hour. Actinomycin D was included 
I 
to prevent the synthesis of second-strand cDNA. 
Table 4.1 Components of “ 1 ®*-round"-reverse transcription buffer 
ist-Round-Reverse Transcription Buffer 
‘ First-Strand Buffer IX 
Actinomycin D SOng/^ iL 
RNasin Plus Ribonuclease Inhibitor (Promega) lU/|iL 
| 驅 _ | 1 1 1 § « ; _ 觀 画 f 願 爾 _ 通 ] 
Reverse Transcription 
mRNA of Target Gene 
, 一 m i E ^ A 
Figure 4.3 Reverse transcription using endogenous miRNAs as primers. 
Endogenous miRNAs ( ) act as primer to start reverse transcription to synthesize 
a first-strand cDNA ( ). 
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4.2.1.3 Collection of Polynucleotides 
After the round of reverse transcription, the reaction mixture was mixed with 
0.02 vol of 10%SDS, and subjected to phenol/chloroform/isoamyl alcohol (25:24:1, pH 
8) (Invitrogen) extraction. Ivol of phenol/chloroform/isoamyl alcohol was added, and 
gently mixed with the reaction mixture. The mixture was then centrifuged at 
13，000rpm for 5 min at 4°C. The aqueous layer was transferred to a new tube, and 
polynucleotides were collected by ethanol precipitation (0.1 vol of 3M sodium acetate 
and 2 vol of 100% ethanol). After thorough mixing, the mixture was centrifuged at 
13,000rpm for 30min at 4°C. Finally, the pellet is air-dried for 15min. 
4.2.1.4 Synthesis of Second-strand cDNAs 
The collected polynucleotides were incubated in the 2"''-round-reverse 
transcription buffer (components are listed in Table 4.2) at 25°C for 10 min, followed 
by 70°C for 30 min. Tth was included in this step because it is a DNA polymerase that 
catalyzes the polymerization of nucleotides into DNA using an RNA template in the 
presence of manganese, which allow for synthesis of DNA complementary to both 
first-strand cDNA and the miRNA (Figure 4.4). • 
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Table 4.2 Components of "2"''-round"-reverse transcription buffer 
2"''-Round-Reverse Transcription Buffer 
“ 1�t-Round’’-Reverse Transcription Buffer 1X 
dNTP 0.2mM 
TtJfpNAPolymerase (Promegai 一 . V i F . 塑 • - 二 ‘ 宣 j 
RNasin Plus Ribonuclease Inhibitor (Promega) lU/|xL 
Second-strand cDNA Synthesis 
Complementary to 1 "-strand cDNA Complementary to miR-106b 
Tth Polymeia^ 广 � ‘ �w 
miRNA 
. Figure 4.4 Second-strand cDNA synthesis. ‘ 
Using RNAs as templates, Tth polymerase can synthesize DNA complementary to both 
the ist-strand cDNA and the miRNA (as shown with the arrow). 
4.2.1.5 PGR Purification of Double-stranded cDNAs 
The double-stranded cDNA was purified with the PCRquick-spin™ PGR 
purification kit (Tech Dragon Ltd.) according to the Manufacture's protocol, and as 
described in the previous chapter. 
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4.2.1.6 Restriction Endonuclease Digestion 
As a result of the PCR purification step, double-stranded cDNA of various lengths 
were produced. For the purpose of subsequent cloning, the cDNA fragments were 
digested with Nlalll (NEB) (Figure 4.5). Nlalll has a recognition sequence (CATG) 
recognizing four nucleotides consisting of A, T, G, and C, thus it is expected that most 
of the unknown target sequences would by chance contain at least one recognition site 
of this endonuclease. lOpL of purified cDNA, and 0.5|j,L of Nlalll were added into Ix 
J 
T4 ligation buffer (NEB) to make up a final vol of 15 i^L. The reaction mixture was 
incubated at 37°C overnight. Note that the digestion was carried in T4 ligation buffer 
(NEB) for subsequent ligation reaction without the need for additional purification step 
to avoid loss of sample. 
Endonuclease Digestion with Nlalll 
Nlal l l Complementary to l"-strand cDNA Complementary to miR-106b 
I 广. r 人• 、 
^ ^ • 
Figure 4.5 Restriction enzyme digestion. 
It is expected that the target gene mRNA would by chance contain the recognition 
sequence of Nlalll (CATG). 
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4.2.1.7 Ligation to Adaptor 
After the enzymatic digestion with Nlalll，the digested fragments were ligated to 
the specially designed adaptor oligonucleotide (Adaptor) for subsequent PCR 
amplification. The sequence for the adaptor oligonucleotide can be found in Table 4.3, 
and the schematic diagram can be found in Figure 4.6. All of the digested products 
were carried to the ligation reaction (luL of T4 ligase (NEB), 20|iM adaptor oligo, 
1 mM ATP) to make up a final volume of 25|j,L. The mixture was incubated for 2 hours 
I 
at room temperature. 
Table 4.3 Sequences of adaptors and primers 
Sequences of Adaptors and Primers 
ilSianie —‘二 „ 旧•丄丄 Sequences (5*->3') . 一 , 
• Adaptor (Adaptor-BamHI-Nlalin CCTACTGAGGGATCCCATG 
丨 Biotin-miR106b (Biotin-miRlo/b)',f 丨 血 — 运 乂 b l G C A ^ A f ? 二 ； 
Longer Adp (L® 皿 g®ir Adp-BamHI-Nlalin AAGCAGTTGTCCTACTGAGGGATCCCATG 
L Nested miR-106b(>j[otI-miR-106b) ^ , , ATGCGGCCGCTGCTGACAGTG^ ？ / j 
I 
Ligation with the Adaptor 
Adaptor ( g 人 C o m p l e m e n t a r y to l"-strand cDNA Complementa^ to miR-106b 
•d i i iTTI I^mmmuifmmnm 丨immrfnTnnnrnTHTniTririTiliTiriW^ 
miRNA 
Figure 4.6 Ligation of adaptor 
After the Nlalll digestion, the sequences are ligated to the adaptor for subsequent 
PCR amplification. 
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4.2.1.8 PGR Amplification with Biotin-labelled miRNA PGR Primers 
The cDNA fragments that were successfully ligated to the adaptor were then 
subjected to PGR amplification with the adaptor primer (Adaptor) and a biotin-labelled 
miR-106b PGR primer (Biotin-miR-106b). The exact sequence of the primers can be 
found in Table 4.3. The concentrations for the reagents used in the PGR amplification 
are summarized in Table 4.4. l|iL of the ligation product was added to the PGR 
amplification reaction mixture (final vol: 20|xL). The PGR amplification conditions 
are listed in Table 4.5. Note that the annealing temperature was experimentally 
determined as the highest temperature able to amplify the miRNA genes from genomic 
DNA. The schematic diagram of this step is shown in Figure 4.7 
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Table 4.4 Reagents for PCR amplification 
PCR Amplification 
丨 : : 翻 • 誦 M l 遍 趣 薩 一 」 : 麵 
Gold Buffer (ABI) IX 
dNTP 0.3mM 
通 隱 臓 觀 i • 醒 
FW primer 0.25^iM 
AmpliTaq Gold® (ABI) lU/^iL 
Table 4.5 PCR amplification condition 
PCR Amplification 
Activation 9 5 ^ 10 min — 
隱 遍 麵 5 廳 塵 • 龜 
Annealing 55°C 30sec 40 
Final Elongation 72°C 10 min 
‘ mms^^mmmmmmmm—^^ 
PCR Amplification with Biotin-Labelled miRNA Primer 
Adaptor Primer _ 
、 V 1 ! ^ “ " | | " " " " " _ ' ' ' " " " " ' " ' • … • … ' … … … … ( B i o t ^ 
Adaptor Biotin-miRl 06b P r i m e r - ^ 
Figure 4.7 PCR amplificaiton with biotin-labelled miRNA primers. 
The 2nd-round PCR amplification involves amplifing the polynucleotides by the 
adaptor primer and the biotin-labelled miR-106b primer 
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4.2.1.9 Capture of Biotin-labelled PCR Fragments 
The amplified products with biotin-labelled PCR primer were captured using the 
SoftLink™ Soft Release Avidin Resin (Promega). The SoftLinkTM Resin was 
prepared according to the manufacturer's protocol for batch-capture. In brief, the resin 
was first equilibrated with Gold Buffer (ABI), and then all of the biotinylated products 
were added to the resin. The capture was incubated overnight at 4°C on rotating 
platforms. Through series of washing with Ix Gold Buffer, the products were finally 
I 
eluted by adding 5mM biotin into the buffer. The resin was gently rocked for 1 hour at 
4°C. The resin was allowed to settle, and centrifuged at <500g for 5 min at 4°C to 
obtain the elution fractions. 
4.2.1.10 Introducing NotI Recognition Sequence 
An aliquot of the collected PCR fragments was amplified with a longer adaptor 
(Longer-Adp) and a nested miR-106b PCR primer containing the NotI recognition 
sequence (Nested miR-106b). The exact sequences of the primers are shown in Table 
4.3. The PCR reagents and the PCR conditions are the same as shown in Table 4.4 and 
4.5. NotI recognition sequence was introduced so that the PCR fragments could be 
ligated into the expression vector, which contains the NotI site. The schematic 
diagram is shown in Figure 4.8. 
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Final-round of PGR Amplification 
BamHI Nlalll 
Longer-Adp Primer 一 
: I•圓丨丨”imimmmmmii"”””"|ummi"immimMiiimmt^^iot{^) 
< N^r^Avidit)/ 
Nested miR-106b Primer 
Figure 4.8 Final round of PCR amplification. 
The final-round of PCR amplification involves using the longer-adp primer and the 
nested miR-106b primer containing the NotI recognition sequence to prepare for 
cloning into the expression vector. 
4.2.1.11 Cloning into the pCR2.1 Vector 
Before cloning the PCR fragments into the pCR2.1 vector (Invitrogen), the 
circular vector was first digested with BamHI (NEB) and NotI (NEB) to cut open the 
N、 
circular vector. The following reaction was prepared in 2 sets: one for the sample 
reaction, while the other for a negative control to check for self-ligated vector. 2\ig of 
the vector was added to the digestion mixture (Ix NEB Buffer 3，lU NotI, lU BamHI) 
making up the total volume of lO i^L. The digestion was incubated at 37°C overnight. 
The digested vector was loaded onto 1% (w/v) agarose gel for gel purification. Gel 
purification was performed using the standard protocol (Qiagen). On the other hand, 
the cDNA fragments were similarly digested with BamHI and NotI and then subjected 
to PCR purification. The schematic diagram can be found in Figure 4.9. 
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Cloning into pCR2.1 
\ Partial sequence of target gene miR-106b / 
Figure 4.9 Cloning potential sequence into the pCR2.1 vector. 
After digesting both the cDNA fragments and the expression vector with the same 
, restriction enzymes (BamHI & NotI)，the potential sequences are ready to be cloned 
into pCR2.1 vector. 
4.2.1.12 Ligation of the cDNA Fragments and the pCR2.1 Vector 
The (NotI & BamHI) digested cDNA fragments and the pCR2.1 expression 
vectors were subject to ligation. The reaction condition is similar to those described in 
section 3.2.5.4 in the previous chapter. 
4.2.1.13 Transformation 
Transformation is performed using DH5a competent cells as described in the 
previous sections. One plate was prepared for the negative control to check for 
self-ligated vectors without insertion of the cDNA fragments, while the other plate 
contains our ligated samples. 
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4.2.1.14 Preparation of Purified Plasmids 
Single bacterial clones were picked and inoculated overnight at 37°C with 
vigorous shaking in 2mL of LB broth to prepare for plasmid purification on the next day. 
96 individual clones were picked, and subjected to purification using the QIAprep Spin 
Miniprep Kit (Qiagen). The procedures were carried out using the standard protocol. 
In brief, the pelleted bacterial cells were re-suspended in 250^L of Buffer PI and 
vortexed until no clumps remained. Then 250jiL of Buffer P2 were mixed gently with 
the mixture. Shortly, 350|4,L of Buffer N3 was added, and centrifuged at 13,000 rpm 
for 10 min at 4°C. The supernatant was loaded onto the QIAprep spin column, and 
centrifuged for 1 min at 13,000 rpm. After discarding the flow-though, TSO i^L of 
Buffer PE was added to the column and centrifuged again for 1 min. The column was 
centrifuged for an additional 1 min to remove residual wash buffer. Then the plasmid 
was eluted by adding 50|iL of Buffer EB through centrifugation. After the purification 
of the plasmids, we have successfully created a library of clones that contain partial 
sequence of our target gene for miR-106b. 
4.2.1.15 Sequencing Analysis of the cDNA Clone Library 
The library of CDNA clones were subjected to sequencing analysis for the 
presence of the potential sequence for the target gene of miR-106b. SOng/^ iL of the 
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purified plasmids were sent to TechDragon Ltd. for sequencing analysis using the Ml3 
FW primer (5'- GTAAAACGACGGCCAG-3'). 
4.2.2 Real-time PCR Target Gene Expression in Cell Lines 
Real-time PCR assay was used to investigate the expression level of ZNF793 and 
CLN8 in ONS-76 and DAOY. The procedures for total RNA extraction from cell 
lines, cDNA preparation from reverse transcription, and the real-time PCR 
amplification were performed similarly to those as described in the previous sections. 
The sequences for the real-time PCR reaction are listed in Table 4.6. Samples were 
prepared in triplicates, and evaluation of the expression levels were normalized to the 
internal control (RPS3). 
Table 4.6 Primers used in real-time PCR amplification for ZNF793 & CLN8 
Target Gene Primers (forward & reverse) 5’+3， 
ZNF793 CGT CTC AGT GGG TTA TGA AGG CAC C 
TCT TCC CAA CAG TGG CAG CCC 
_ _ _ _ _ 薩 _ 讓 _ _ 顯 誦 i ^ M . 
4.2.3 Real-time PCR Target Gene Expression Upon Inhibition of 
miR-106b 
Real-time PCR assay was used to investigate the effect of inhibiting miR-106b 
on the gene expression of ZNF793 and CLN8 in DAOY. The procedures for 
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transfection of microRNA inhibitor, total RNA extraction, cDNA preparation from 
reverse transcription, and the real-time PGR amplification were performed similarly 
to those as described in the previous sections. The sequences for the real-time PCR 
reaction are listed in Table 4.6. Samples were prepared in triplicate, and evaluation 
of the expression levels were normalized to the internal control (RPS3). 
4.2.4 Cloning of Potential Target Genes into pMIR Luciferase 
Expression Vector 
The cloning of the potential target gene ZNF793 and CLN8 was performed 
similarly as described in the chapter (section 3.2.5). The sequences of ZNF793 3'UTR, 
” and CLN8 3'UTR were prepared from genomic DNA using PCR amplification as 
previously mentioned. The PCR primers are listed in Table 4.7. 
Table 4.7 PCR primers for 3'UTR cloning 
PCR Primers (S’"^ 3，) 
I 7NTF79i^ ， c , f \ � S t a f t Site • : 
ZNF793-FW GTCTGCTTCCCTG AGTTCT 16101'^  
丨 ZNF793-RV,��…AACTGGTTTGGCATjTCTTGG,； � 腳 I 
CLN8 
！ CLNS-F^V, , : G C G 經 睡 觀 虚 ： 誦 
CLN8-RV TGGTGGGGGTTAAACTCCAA 17717 化 
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4.2.5 Site-directed Mutagenesis 
According to our sequencing analysis, the predicted seed region for miR-106b was 
mutated in the 3'UTR of CLN8 using the QuickChange®II Site-Directed Mutagenesis 
Kit (Stratagene). The procedures were performed according to the standard protocol 
and as in section 3.2.6, and the mutation primers are listed in Table 4.8. 
Table 4.8 Primers for site-directed mutagenesis of CLN8 
CLN8 Mutation Primer Sequence (5，">3，) •• 
CLN8-Mut-RV GCCTCGGCCTCCCATCCTCCTGGGATTACGTCG 
**The bold nucleotides were the mutated sites where G replaces C, while A replaces T 
and vice versa. 
4.2.6 Luciferase Reporter Assay 
Luciferase reporter assay was performed for verification of the potential target 
genes (ZNF-793 & CLN8). The assay was performed similarly as previously 




4.3.1 Sequencing Analysis of the cDNA Clone-Library 
The clones in the cDNA library are expected to contain partial sequence of the 
target gene; therefore, sequencing analysis can reveal the identity of the target genes. 
The schematic diagram of the expected construct of our cDNA library is shown in 
Figure 4.10. The potential sequence of our target gene should be enclosed by the two ’ 
restriction enzymes that were used for cloning into the expression vector (BamHI & 
NotI). As depicted in the diagram, the miR-106b sequence should follow immediately 
after our potential sequence. Notice that the potential sequence should only contain 
� partial sequence of the target gene because it was randomly truncated by NIalll for the 
purpose of cloning into the expression vector. However, through sequencing analysis 
of the partial sequence with the use of the BLAST program, we should be able to find 
the identity of the potential target genes. Having said that, there are several criteria for 
analyzing our clones: 
1) Clones should contain the full sequence of miR-106b 
2) The length of the potential sequence is preferably >10 base-pairs 
3) Blast search of the potential sequence falls in the 3'UTR of mRNA of a gene 
4) Regions on the mRNA following the potential sequence should preferably show 
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partial homology to miR-106b recognition sequence 
Construct of cDNA Clone 
Vector BamHI Partial Sequence of Target Gene miR-106b NotI Vector 
*M13FW 
Figure 4.10 Final construct of a cDNA clone. 
Shown is the expected final construct of a cDNA clone prepared by series of 
reverse-transcriptions using miR-106b as an endogenous primer in the experimental 
approach. Ml3 FW was used as the sequencing primer. 
96 clones were sent for sequencing analysis. The statistical summary is presented 
/ 
in Table 4.9. Of the 96 clones sent for sequencing analysis, 77 showed a clear 
sequencing result. 3 out of 77 clones were not able to re-locate the full length 
sequence of miR-106b，suggesting that they were likely to be clones containing random 
sequences. Of the 74 potential sequences isolated, 10 of them fall on the 3'UTR of a 
transcript. The exact sequence of the potential sequences and the locations on the 
corresponding target gene are listed in Table 4.10. After the blast analysis, ZNF793 
and CLN8 were selected based on their homology to miR-106b at the seed region. The 
detailed blast results are shown in Figure 4.11. ZNF793 and CLN8 were selected for 
further downstream verification because they show extensive homology to the seed 
region of miR-106b (Figure 4.11 marked by asterisks). 
96 
Table 4.9 Statistical summary of the cDNA library 
cDNA Library (miR-106b) 
Clear sequencing result .、？,"，. 乂丄 ） 一 77/9^1_):� : . . :二―： j 
Presence of miR-106b sequence 74/77 (96%) 
Potential sequence falls on a transcript 22/74 (30%) 
‘Potential-sequence falls on p r ^ 
Table 4.10 Blast result for potential sequences 
cDNA Library (miR-106b) 
Clone# Potential Sequence Gene Location 
7 TGCAGAAGTCCGCGGACGAGA H. sapiens chromosome 20 open Exon4 
AAAGCCGCAGCACGTTGACCA reading frame 54 
GAGGGAACATGGGATCCGAG 
19 GTGAGCCACCCCACCCAGCTGA H. sapiens zinc finger protein 793 3'UTR 
ACTTTTCTTTTGTACATG (ZNF793) 
H. sapiens ceroid-lipofuscinosis, 3'UTR 
neuronal 8 (epilepsy, progressive 
with mental retardation) (CLN8) 
23 GGTGCATGGGATCCGAGC H. sapiens protein tyrosine 5'UTR 
phosphatase, receptor type, S 
(PTPRS) 
H. sapiens potassium voltage-gated 3'UTR 
channel, Saw-related subfamily, 
member 1 (KCNCl) 
24 CAGATGTGTAGACGCCCCATGG H. sapiens protocadherin 20 Exon4 
(PCDH20) 
37 AAGGACAACGTGGCATG • Homo sapiens C-type lectin domain 3'UTR, 
family 16’ member A(CLEC16A) 
38 GATGGGAGGCCATG H. sapiens protein phosphatase 3'UTR 
methylesterase 1 (PPMEl) 
H. sapiens F-box and leucine-rich 3'UTR 
repeat protein 7 (FBXL7) 
44 GAAGCAATGGGCCATG H. sapiens hypothetical protein 3'UTR 
LOG 100291302 Chemokine XC 
receptor 1 
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61 TAAGCGTGATGACACATG Homo sapiens solute carrier family 3'UTR 
7 (cationic amino acid transporter, 
y+ system, member 1 (SLC7A1) 
86 CGTGCTGATGGAACTGTTGTAC H. sapiens c-ros oncogene 1, Exon 20 
CATG receptor tyrosine kinase (ROS1) 
H. sapiens minichromosome Exon 9 
maintenance complex component 3 
associated protein (MCM3Ap) 
96 GAACAACAGAGTAGGGAAACG H. sapiens complement component Exon 20 
CATG 3 (C3) 
104 GAGGCTCTTAAGCAGGGAGAA H. sapiens phosphodiesterase 6A, Exon 13 
CATG cGMP-specific, rod, alpha (PDE6A) 
108 GGACAGGGCGGTCATG H. sapiens v-yes-1 Yamaguchi Exon 13 
sarcoma viral related ocogene ‘ 
, homolog (LYN) 
H. sapiens purinergic receptor P2Y, Exon 2 
G-protein coupled, 8 (P2RY8) 
H. sapiens GATA binding protein 3 Exon 3 
(GATA3), transcript variant 1 
H. sapiens serine peptidase 3'UTR 
inhibitor, Kunitz type, 2 (SPINT2), 
� mRNA 
142 GGAAACAGGGCATCTCAGATGG H. sapiens filamin C, gamma (actin Exon 39 • 
CCCCAAACATG binding protein 280) (FLNC), 
transcript variant 2 & 1 
H. sapiens nemo-like kinase (NLK) Exon 11 
152 CAGGAAGGAGCAGGGGGTGAA H. sapiens eukaryotic translation 3'UTR 
















































































































































































































































































































































































































































































































































































































































































































































































































































4.3.2 Expression Levels of Candidate Genes in MB Cell Lines 
The expression levels of ZNF793 and CLN8 were first checked in ONS-76 and 
DAOY by qRT-PCR. Relatively lower expression of the mRNA level for both 
ZNF793 (Figure 4.12A) and CLN8 (Figure 4.12B) was observed in both cell lines 
(especially in DAOY) as compared to the normal cerebellum. The down-regulation of 
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Figure 4.12 Quantitative real-time PCR for candidate genes. 
Relative mRNA expression levels ofZNF793 (Figure 4.12A)，and CLN8 (Figure 4.12B) 
compared to those in normal cerebellum. Each expression levels were normalized 
with their respective reference gene (RPS3) 士SD. 
4.3.3 Effects of Anti-miR-106b Inhibitors on 3'UTR of Target Genes 
Because miRNA can regulate its targets through both transcriptional and 
translational regulations, real-time PCR amplification was performed to examine the 
effect of anti-miR-106b inhibitor on the mRNA level of ZNF793 and CLN8. There 
was no significant change in mRNA transcript levels for both ZNF793 and CLN8 upon 
treatment with anti-miR-106b inhibitor in DAOY (Figure 4.13A & B). These data 
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Figure 4.13 Changes in mRNA level upon treatment with miRNA inhibitors. 
Quantitative real-time PGR was used to examine the temporal changes of mRNA 
transcription of ZNF793 (Fig 4.13 A), and CLN8 (Fig 4.13B) in DAOY upon treatment 
with anti-miR-106b inhibitor. The average fold-change was first normalized using the 
internal reference gene (RPS3), then compared to the negative control 士SD. No 
significant change in mRNA level is observed. 
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4.3.4 Verification of Candidate Genes 
Dual-luciferase reporter assay was used to verify if ZNF793 and CLN8 are true 
targets for miR-106b. Regions on the 3'UTR of ZNF793 (ZNF793-pMIR) and CLN8 
(CLN8-pMIR) containing the potential target sites were separately cloned into the 
luciferase expression vector. Upon treatment with anti-miR-106b, there was no 
significant change in luciferase activities observed in ZNF793-pMIR (Figure 4.14A). 
On the other hand, significant increase in luciferase activity was observed for 
CLN8-pMIR upon treatment with miR-106b inhibitors (Figure 4.14B) suggesting that 
CLN8 may likely be a target gene regulated by miR-106b. 
A 
pMIR-ZNF793 
> 120 -1 
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, Figure 4.14 Relative luciferase activity of ZNF793-pMIR and CLN8-pMIR. 
The histogram in Fig 4.14A shows the levels of luciferase activity of ZNF793-pMIR 
after treatment with anti-miR-106b in DAOY. The % of luciferase activities were 
normalized with renilla activity, and compared to their respective negative controls. 
Statistical comparisons were performed with Student /-test. Error bars represented SD. 
There was no significant change in luciferase activity observed. The histogram in Fig 
4.14B shows that there was a significant increase (p<0.02) in luciferase activity for 
‘ CLN8-pMIR after treatment with miR-106b inhibitor (asterisks). 
4.3.5 Verification of Target Sites with Site-directed Mutagenesis 
To further confirm whether the target site mapped from our cDNA-clone is the 
critical target region, site-specific mutation was induced at the proposed miR-106b 
target region. The construct with the mutated region is depicted in Figure 4.15. 
Under the negative control condition (without treatment of miR-106b), endogenous 
miR-106b would bind onto the proposed miR-106b recognition site on the wild-type 
CLN8 3'UTR suppressing the luciferase activity. Upon treatment with miR-106b 
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inhibitors, the endogenous miR-106b are inhibited, which would lead to a relief of the 
suppression of luciferase activity on the wild-type construct. As a result, an increase 
in the change in luciferase activity between the treatment group and the respective 
negative control is expected for the wild-type construct. On the other hand, if the 
mutated miR-106b recognition site were the true target region regulated by miR-106b, 
then the change in luciferase activity between samples treated with miR-106b inhibitor 
and the respective negative control should be minimal because the miR-106b 
recognition site is disrupted by the mutation. In other words, no suppression of 
luciferase activity (no change) is expected regardless if the samples were treated with 
miR-106b inhibitors or the negative control, because the mutated site is no longer 
, susceptible to miR-106b regulation. From our data, the wild-type CLN8-pMIR, as 
expected, showed a significant increase in luciferase activity upon treatment with 
anti-miR-106b (Figure 4.16). After mutating the proposed miR-106b recognition site 
(Rl), the change in luciferase activity was suppressed as compared to the change 
observed for the wild-type construct, indicating the importance of the recognition site 
and that it is likely the critical region targeted by miR-106b. 
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CACGT CLN8-pMIR 
Luciferase P(A) fyjjn^ 
3 'UTR CLN8 (Wild-type) 
R1 
GAGGA CLN8-PMIR 
Luciferase C L N 8 口 � （ R ! @ 柳，485，487) 
Figure 4.15 Mutation construct for CLN8-pMIR. 
Shown above are the luciferase construct for the wild-type CLN8-pMIR, and the 
construct carrying specific mutation at 483''^ 485^ and 487也 bp on the 3'UTR of 
CLN8. Note that the bold nucleotides indicate the mutated nucleotides where they are 
replaced by their complementary nucleotides. 
Site Mutagenesis (pMIR-CLN8) 
a> 
> * * 
圣 ， „ 。 ** T T •An t i -miR106b 
li i r ^ i * 
11 5 � � _ ’a-
i _ i _ _ .MO. 
° R1 Wildtype 
Figure 4.16 Site-directed mutagenesis of CLN8 3'UTR. 
Shown is the relative luciferase activity for the wild-type and the mutated CLN8-pMIR. 
Luciferase activity was normalized with Renilla activity, and compared to their 
respective negative controls 士SD. Asterisks indicate Student Mest p<0.04. 
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4.4 Discussion 
The biochemical approach in identifying target genes for specific miRNAs relies on 
the formation of base pairing between the miRNAs and their target genes; therefore, the 
miRNAs act as endogenous primers in the reverse-transcription reaction to synthesize 
first-strand cDNAs. However, to what efficiency can the miRNAs bind to their targets 
in vitro still remains unknown. From the sequencing data of our cDNA-cIone library, 
many of the clones (-26%) carry only very short fragments (<10bp) of the potential 
/ • 
sequence (Table 4.10). This indicates that the initial reverse-transcription using 
miRNAs as primers may not be too efficient. Also, around 70% of the clones were 
false positives that do not fall on regions of a transcript (Table 4.9). These clones were 
likely amplified from random genomic DNA template during the amplification step 
using the adaptor primer and the biotin miR-106b primer. To lower the rate of false 
positive, a possible approach is to employ a shorter biotin-miRNA primer that excludes 
several nucleotides of the miRNA seed sequence from the 3' end. This may act as a 
screening step to select out false positive clones that do not contain the full sequence of 
the miRNA. For instance, if the potential sequences were amplified merely using our 
adaptor primer and the "shortened" biotin-miRNA primers from random genomic DNA 
templates, the chance of having false positives possessing the exact full length of our 
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miRNA recognition sequence including the purposely left out nucleotides is very slim. 
Despite the false positive clones, ZNF793 and CLN8 were isolated and chosen as 
potential candidates for further verification. Luciferase reporter assays indicated that 
ZNF793 were not directly involved in the regulation of miR-106b. On the other hand, 
luciferase reporter assay indicated that the 3'UTR of CLN8 interacts with miR-106b 
(Figure 4.14B). Site-directed mutagenesis further confirmed the critical target site at 
483rd -487th bp on the 3'UTR of CLN8 (Figure 4.16). We determined that CLN8 is a ‘ 
target gene regulated by miR-106b. CLN8, also known as ceroid-lipofuscinosis, 
neuronal 8，is located on chromosome 8p23. It encodes a transmembrane protein 
belonging to the TLC domain, which is responsible for lipid synthesis, transport, or 
sensing (Ashburner et al. 2000). CLN8 is identified as one of the eight causative genes 
responsible for neuronal ceroid lipofuscinoses (NCL) (Vantaggiato et al. 2009). 
Patients with NCL usually have progressive ocular and cerebral dysfunction, which 
leads to cognitive/motor dysfunction and uncontrolled seizures (Wisniewski et al. 
2001). More specifically, homozygous mutations in CLN8 are associated with 
progressive epilepsy and mental retardation (Vantaggiato et al. 2009). Although the 
physiological function of the protein encoded by CLN8 and the pathogenic 
mechanism(s) are still unknown, however, a recent study conducted by Vantaggiato et 
al indicated that CLN8 plays a role in cell proliferation during neuronal differentiation, 
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as well as in protection against cell death (Vantaggiato et al. 2009). As a future 
direction, we could study the function of CLN8 in MB through gene silencing approach. 
Collectively in this chapter, our data suggest that our method not only can identify 
target genes of specific miRNA, but also able to isolate the critical recognition site on 
the 3'UTR. 
The knowledge on the pairing of mRNA and miRNAs such as Lin-4 and let-7 in 
C.elegans is well studied (Yoon and De Micheli 2006)，and it provides, the basic 
‘ guidelines as to how miRNA interacts with target genes. However, this approach may 
not be equally efficient in human models as it is not surprising that the complexity of 
the gene regulatory network increases proportionally as the function of genomic 
, complexity of an organism (Olive et al. 2010). From the top 10 results (-1500 clones) 
from 34 experiments, Andachi had eventually reached 74% efficient in identifying 
targets in his lin-14 model. It is still too early to judge whether the experimental 
approach used in this chapter is efficient or not as there are still other targets remained 
to be verified (Table 4.10). Perhaps, more trials are needed to improve the overall 
efficiency. Another factor to be considered in future trials is that some of the potential 
sequences fall in regions other than the 3'UTR (Table 4.10). Although in our study, 
we have primarily focused on potential sequences that fall on the 3'UTR, regulations of 
target genes through 5'UTRs are not rare events. K was demonstrated in Grey et al.'s 
109 
study of viral miRNA that miRNA meditates translational repression of multiple 
cellular genes by targeting their 5'UTR (Grey et al. 2010). Also, a study employed the 
use of tagging of the miRNA to identify targets of miRNA regulation had found that 
miR-10a can target mRNAs encoding ribosomal proteins through their 5'UTRs for 
enhancement of translation (Orom and Lund 2010). These data suggest that the well 
known complementary binding mechanism of miRNAs and mRNAs may be one of the 
many mechanisms as to how miRNA regulate their targets, and that targeting through ‘ 




CHAPTER 5: FUNCTIONAL ASSAYS 
5.1 Introduction- Functional Investigation of miR-106b-25 Cluster 
The functions of microRNAs were originally described during normal development 
(Olive et al. 2010). Nowadays, in addition to normal development, miRNAs have 
emerged as important components of the oncogenic and suppressor network, playing 
important regulatory roles in cellular processes altered during tumour development 
(Olive et al. 2010). With the advance in molecular biology in the past decades, many 
initial studies were conducted to explore the expression patterns of miRNAs. Many 
miRNA profiling studies have indicated that aberrant expressions of miRNAs are 
frequently associated with various human cancers. Many reports have further 
� demonstrated that the identified aberrant signatures of miRNAs are associated with 
distinctive clinical and pathological features that contribute to the phenotypes of the 
cancers (Calin and Croce 2006)，thus these miRNAs are known as oncomiRs 
processing oncogenic properties or acting like tumor suppressor genes (Ambs et al. 
2008). In particular, miR-106b-25 cluster was found to be up-regulated in primary 
MBs and in various MB cell lines. Up-regulation of miR-106b-25 cluster was also 
reported in other cancers including breast cancers, colon cancers, prostate cancers, and 
hepatocellular carcinoma (HCC) (Volinia et al. 2006). The miR-106b-25 cluster has 






demonstrated that the expression of miR-106b-25 cluster is necessary for cell 
proliferation and for anchorage-independent growth in HCC (Li et al. 2009). In 
addition, Li et al. have identified the transcription factor E2F1 as a target gene for 
miR-106b and miR-93, possibly inducing apoptosis by preventing excessively high 
expression of E2F1 (Li et al. 2009). In a study that attempted to functionally classify 
specific miRNAs and transcripts known for particular cellular pathways, several 
members of the miR-106b family were found to correlate with cell cycle-related 
transcripts (Ivanovska et al. 2008). More specifically, miR-106b was correlated with 
transcripts involved in DNA replication and mitosis, while miR-93 was correlated with 
regulator of DNA replication (Ivanovska et al. 2008). These data suggest that the 
up-regulation of the miR-106b-25 cluster may contribute to the highly proliferative 
nature of certain tumours (Ivanovska et al. 2008). Therefore, it is important to 
investigate the functional roles associated with the aberrantly expressed miR-106b-25 
cluster. In order to investigate the functional importance of the miR-106b-25 cluster in 
MB, we have performed several functional assays: 1) MTT Assay, 2) Cell Cycle Profile, 
3) BrdU Cell Proliferation Assay, and 4) Wound Healing Assay. 
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5.2 Methods 
5.2.1 Cell Culture 
ONS-76 were obtained from American Type Culture Collection (ATCC, Rockville, 
MD, USA) and maintained in RPMI (Gibco Invitrogen Corporation) supplemented 
with 10% FBS (Gibco Invitrogen Corporation). Culturing procedures and conditions 
were performed similarly as described in section 3.2.2.1. ‘ 
I 
5.2.2 Over-expression of miR-106b Mimic 
Over-expression of miR-106b mimic (Ambion) was carried out using Lipo2000 
according to the standard protocol provided by the manufacturer. Ectopic expression 
of miR-106b mimic was assessed by co-transfecting the mimic and the luciferase 
expression vector cloned with the reverse complement sequence of miR-106b 
(pMIR-106b). The co-transfection and the luciferase reporter assay were performed 
similarly as described in chapter 3’ section 3.2.3.2.1 with the exception of replacing the 
inhibitor with the miR-106b mimic and its corresponding negative controls. 
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5.2.3 MTT Assay 
Inhibition of the miR-106b-25 cluster: 
The effect of inhibiting the miR-106b-25 cluster on cell growth for adherent cell 
lines was studied using MTT assay. 1.2x10^ ONS-76 cells, and 1.4x10^ DAOY cells 
were separately seeded into each well in a total volume of lOO i^L culture medium. 
Transient transfections of 5 pmol of each of the microRNA inhibitors 
(anti-miR-106b/anti-miR-93/anti-niiR-25, negative, and mock (DEPC-H2O) were 
I 
transfected into the cells by Lipo2000 according to the suggested concentration for 
96-well culture vessel. Each treatment was prepared in 8 replicates. The cell growth 
was assessed at day 4 by the MTT assay (Cayman Chemical, USA). 1/10 volume of 
� the tetrazolium salt (MTT) was added into each well, and incubated for 4 hours at 37°C 
incubator. Residuals were removed, and an equal volume of dimethyl sulfoxide 
(DMSO) was added to each well to solubilize the formazan dye. The absorbance of 
the mixture was measured at 570nm, and normalized using the reference wavelength at 
630nm. 
Over-expression with miR-106b mimic: 
The effect of over-expressing miR-106b on cell growth in DAOY was examined 
similarly as described above for the exception of using miR-106b mimic instead of 
inhibitors. 114 
5.2.4 ICso ofCisplatin 
The half maximal inhibitory concentration ( I C 5 0 ) was determined before testing 
the effect of inhibition of the miR-106-25 cluster on the sensitivity of cisplatin (Fluka). 
Mock transfection for DAOY cells were first performed in 6-well plate as previously 
mentioned. One day post-transfection, 1.2x10'^  cells were re-plated into 96-well plate 
ready for treatment with various concentration of cisplatin. The tested concentrations 
of cisplatin were as follows: 8|xg/mL, 6|xg/niL, 4ng/mL, 3|xg/mL, 2|ig/mL，l|ig/mL, 
I 
500ng/mL, and 250ng/mL. At day 4，cells were subjected to MTT assay as mentioned 
above. 
5.2.5 MTT Assay with Cisplatin Treatment 
The sensitivity to cisplatin upon inhibition of the miR-106b-25 cluster in DAOY 
was examined using MTT assay. Transfection of microRNA inhibitors and the 
negative control were first performed in 6-well plate as described previously. One day 
post-transfection, the treated cells (1.2xl04 cells/well) were re-plated into 96-well plate 
ready for treatment with cisplatin. 0.25|xg/mL of cisplatin was added to each well too 
make up the total of ISO i^L volume. At day 4，cells were collected for MTT assay as 
described above. 
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5.2.6 Cell Cycle 
Propidium iodide (PI (P4710), Sigma Aldrich) staining and flow cytometry were 
used to examine the stage of the cell cycle for DAOY cells upon inhibition of the 
miR-106b-25 cluster. Transfection of the microRNA inhibitors (anti-miR-106b/ 
anti-miR-93/anti-miR-25/negative control) and mock transfections were performed in 
6-well plates similarly as described earlier. Samples were prepared in triplicates. At 
24hr post-transfection, cells were harvested for flow cytometry analysis. In brief, cells 
I 
were first washed with Ix PBS, and then trypsinized. After centrifugation, the cell 
pellets were re-suspended in ImL of IxPBS. Then 4 mL of absolute ethanol at -20°C 
were added in dropwise to the cell suspension for fixation of the cells for 15 min. Then 
cells were pellet, and ethanol was discarded. Cells were subjected to rehydration using 
5mL of IxPBS. After centrifugation, the cell pellets were re-suspended in a total of 
200^iL of TE buffer (ImL Tris-EDTA, S^L of PI, and RNase). Then they were 
aliquot onto 96-well plate and incubated in the dark for 30 min for subsequent analysis 
using the BD FACS Array Bioanalyzer. A total of 10,000 events were counted for each 
sample. Data were analyzed with Flow Jo software (Tree Star). 
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5.2.7 BrdU Cell Proliferation Assay 
Cell proliferation was evaluated by bromodeoxyuridine (BrdU) incorporation 
analysis, (BD Pharmingen™). Transfection of microRNA inhibitors for DAOY in 
6-well plate was performed similarly as described earlier. After 24 hours of 
transfection, DAOY cells were pulsed with lOjiM of BrdU for 1 hour. After the 
incorporation, cells were fixed in 2mL of ice-cold 80% ethanol for 4 hours. After the 
fixation, cell pellets were collected, and re-suspended in 2mL of 2M HCl for 10 min. 
I 
Subsequently, cells were subjected to several washes with IxPBS with ImM EDTA. 
Finally, cell pellets were re-suspended in 50pL of fluorescein 
isothiocyanate-conjugated anti-BrdU antibody in 1:4 ratio with the supplied incubation 
buffer, and incubated for 1 hr at 37°C. The percentage of cells labeled with BrdU was 
determined using flow cytometry. 
5.2.8 Wound Healing Assay 
The effect of inhibiting the miR-106b-25 cluster on cell migration was examined 
using the wound healing assay. DAOY cells were first transfected with microRNA 
inhibitors, negative controls, and mock controls in 60mm culture dishes according to 
the recommended concentration suggested by the manufacturers. In brief, 200 pmol 
of each of the microRNA inhibitors or the negative control were diluted in SOO^ iL of 
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OPTI-MEM, while lO i^L of Lipo2000 was diluted in SOO^ iL ofOPTI-MEM for 5 min. 
Then the two were mixed together and incubated for another 20 min. ImL of the 
mixture was added to each of the appropriate wells containing 5mL of fresh medium. 
At 24 hours post-transfection, 2.2x10^ cells were re-plated into 6-well plate, and let 
settled overnight. The next day, the monolayer was scratched with sterile tips, briefly 
washed with Ix PBS. The cells were maintained in fresh medium, and the wound 
sizes were observed under microscope and photographed at different time points (0 and 




5.3.1 Effects of Inhibition of miR-106b-25 Cluster on Cell Growth 
The effects of inhibition of miR-106b-25 cluster on cell growth were examined in 
two MB cell lines (ONS-76, and DAOY) using MTT assay. Inhibiting miR-106b and 
miR-25 resulted in significant reductions in cell growth for ONS-76 (Figure 5.1 A), and 
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Figure 5.1 Effects of inhibition of miR-106b-25 cluster on cell growth. 
Examination of cell growth was achieved using the MTT assay ONS-76 and DAOY. 
Measurements were taken at Day 4. The relative cell growth for each treatment was 
compared to the average of their respective negative controls (anti-miR negative 
control) 士SD. All assays were performed in 8 replicates. Asterisks indicate Student 
/-test with p<0.00. 
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5.3.2 Cell Cycle Distribution Analysis 
Propidium iodide (PI) staining and flow cytometry were used to study the effects 
of inhibition of the miR-106b-25 cluster on cell cycle progression in DAOY. PI binds 
to DNA by intercalating between the bases of DNA; therefore, cell cycle profile can be 
deduced by monitoring its fluorescent signals. The cell cycle progression was 
analyzed after 24hr post-transfection of specific microRNA inhibitors. Overall, 
inhibiting miR-106-25 cluster did not result in significant change in the distribution of 
I 
the cell cycle profile (Figure 5.2A &B). 
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Figure 5.2 Cell cycle progression profile. 
Cell cycle profiles were analyzed using flow cytometry. Shown in Figure 5.2A are the 
histograms of cell numbers (y-axis) against DNA content (x axis) for treatments with 
different microRNA inhibitors. Shown in Figure 5.2B is the summary chart for the 
cell cycle distribution for each treatment. There were no significant changes or shift in 
the cell cycle distribution upon treatment with anti-miR-106b/miR-93/miR-25 as 
compared to the negative controls. 
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5.3.3 Sensitivity to Cisplatin 
As an anti-cancer drug that can cross-link DNA, cisplatin was used to examine the 
effect of inhibition of the miR-106b-25 cluster on cell growth. First, the 50% 
inhibition concentration ( I C 5 0 ) for cisplatin on DAOY was determined to be 0.25}xg/mL 
as shown in Figure 5.3. DAOY cells treated with cisplatin were co-transfected with 
anti-miR-106b, anti-miR-93, and anti-miR-25 inhibitors, and cell growth was 
monitored using the MTT assay. Upon treatment with the miRNA inhibitors, there 
were no significant changes in cell growth (Figure 5.4). In order words, inhibiting this 
cluster of microRNA has no effect on the sensitivity to cisplatin treatment. 
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Figure 5.3 ICsn for cisplatin in DAOY. 
The graph shows the percentage of viable cells after treatment with different 
concentration of cisplatin. The data points were shown as an average of 8 replicates. 
The I C 5 0 is shown in the dashed lines, and it's approximated to be 0.25^g/mL. 
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Figure 5.4 Cell growth after treatment with cisplatin in DAOY. 
Upon treatment with 0.25|ig/mL of cisplatin and various microRNA inhibitors 
(anti-miR 106b, anti-miR93, and anti-miR25), there was no significant change in the 
percentage of viable cells observed compared to the negative control (treatment with 
I 
anti-miR negative#l). Samples were taken from the average of 8 replicates, and 
expressed as % of viable cells relative to the control 土SD. 
5.3.4 Cell Proliferation Assay 
The effects of inhibiting the miR-106b-25 cluster on cell proliferation were 
examined using the immunofluorescent staining of incorporated bromodeoxyuridine 
(BrdU) followed by flow cytometry analysis to determine the frequency of individual 
cells that have synthesized DNA (S phase of the cell cycle). Treatment with inhibitors 
of miR-106b, miR-93, and miR-25 in DAOY cells resulted in a trend of decrease in 
cells in S Phase. Specifically, anti-miR-25 decreased up to approximately 10% of the 
cells in S phase (Figure 5.5B). 
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Figure 5.5 Effect of inhibition of miR-106b-25 cluster on cell proliferation. 
Shown in Figure 5.5A are the scatter plots of fluorescence intensities of BrdU 
incorporation in log scale (y-axis) against DNA content (x-axis). The gated regions 
represent the S-phase populations (positive for BrdU incorporation). Figure 5.5B is 
the bar chart representing the percentage of cells in S phase. 
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5.3.5 Cell Motility 
Wounds scratched on DAOY monolayer cells were monitored at 0，and 24 hours to 
investigate the migration properties upon inhibition of miR-106b, miR-93, and miR-25. 
Upon treatment with anti-miR 106b, anti-miR-93, and anti-miR-25, there was a trend of 
decrease in cell motility. Upon treatments with the inhibitors, there were 
approximately 20% decreases in the percentage of wound recovered by the cells 
(Figure 5.6A&B). 
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Figure 5.6A & 5.6B Wound healing assays. 
Figure 5.6A, the monolayer was scratched with sterile pipette tips, followed by washing 
to remove cellular debris. Cell migration was observed at 24hr by microscopy. 
Figure 5.6B shows the relative percentage of wound recovered by cells after treatment 
with different microRNA inhibitors (miR-106b/miR-93/miR-25) 土SD.. The 
percentages were calculated from an average of triplicates for each treatment. 
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5.3.6 Efficiency of Over-expression Using miR-106b Mimic 
The efficiency of over-expressing miR-106b was examined using dual luciferase 
reporter assay. Over-expression of miR-106b in DAOY cells was achieved by 
transfection of synthetic mature miR-106b (miR-106b mimic). The miR-106b mimic 
was co-transfected along with the luciferase expression vector cloned with the 
complementary target sequence of the miRNA. Inhibition of luciferase activity (-97%) 
resulted from excess miR-106 mimic binding onto the luciferase expression vector was 
observed (Figure 5.7). These data suggests that miR-106b mimic was successfully 
transfected into DAOY and mediates its over-expression effects. 
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Figure 5.7 Efficiency of over-expression of miR-106b mimic on cell growth. 
The suppression of the luciferase activity of the pMIR-reporter cloned with the 
complementary sequence of miR-106b was used to examine the efficiency of 
over-expressing miR-106b mimic in DAOY cells. Measurements were taken as an 
average of triplicates 士SD. Asterisk indicates Student Mest with pO.OO. 
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5.3.7 Effects of miR-106b on Cell Growth 
The effect of over-expressing miR-106b on the cell growth of DAOY was 
examined using the MTT assay. By over-expressing miR-106b using the miRNA 
mimic, cell growth was significantly enhanced. The enhanced growth observed when 
over-expressing miR-106b is consistent with the decrease in growth when miR-106b 
was inhibited (Figure 5.8). 
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� Figure 5.8 Effects of miR-106b inhibition or over-expression on cell growth. 
Measurements of the MTT assay were taken at Day 4. The relative cell growth for 
each treatment was compared to the average of their respective negative controls 
士SD. All assays were performed in 8 replicates. Asterisks indicate p<0.00. 
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5.4 Discussion 
Shifting our gears from the exquisite identification of specific targets involved in 
one of the many important cellular pathways, in this chapter we have investigated the 
effects of the dyregulated expression of the miR-106b-25 cluster on some major 
functional properties in MB cell lines in hope of bringing a broader view on the roles of 
this cluster of microRNA in MB. As demonstrated in chapter 3, the miR-106b-25 
cluster was found to be abberrantly expressed in primary MB, and have confirmed in 
I 
various MB cell lines as well. Altered expressions of this cluster of microRNA have 
also been demonstrated in other human cancers including hepatocellular carcinomas, 
lymphocytic leukemia, lung cancers, and breast cancers (Calin et al. 2002; Takamizawa 
et al. 2004; lorio et al. 2005; Li et al. 2009), suggesting crucial roles of this cluster in 
cancers. In fact, miRNA genes can occur in clusters, and transcribed as polycistronic 
transcripts (Li et al. 2009). The miR-106b-25 cluster has two other paralogs, 
miR-17-92 cluster and miR-106a-363 cluster (Li et al. 2009). Among microRNAs, the 
miR-17-92 cluster is the best characterized and is the most potent oncogenic microRNA 
(Li et al. 2009). Because the miR-106b-25 cluster is the paralog of the miR-17-92, we 
speculate that they share similar functional roles. One of the very first functional 
assays tested was the cell growth assay. Upon inhibition of the miR-106b-25 cluster, 
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decrease in cell growth was observed for ONS-76 and DAOY. More specifically, there 
was significant decrease in cell growth when ONS-76 cells were treated with 
anti-miR-106b，and anti-miR-25. On the other hand, significant decrease in cell 
growth was observed in DAOY cells that were treated with anti-miR-106b. To deduce 
the causes responsible for the decrease in cell growth observed, cell cycle profile was 
examined. However, no shift in cell cycle distribution was observed when cells were 
treated with miRNA inhibitors of the miR-106b-25 cluster. Then we further ‘ 
‘ investigated whether the inhibition of the miR-106b-25 cluster would be able to further 
decrease cell growth on top of the cisplatin-induced cell death, however, our data 
indicated the inhibition of miR-106b-25 cluster did not contribute to the sensitivity of 
cisplatin. We further examined the cell proliferation using the BrdU cell proliferation 
assay. It was observed that there was a general trend of decrease in cell proliferation. 
Cell migration assays also revealed that cells have experienced a slower migration rate 
upon treatment with the miRNA inhibitors. MTT assays rely on the number of 
metabolically active (growing) cells, the decrease in cell growth observed after 
^ treatment with anti-miR-106b inhibitor may be caused by the hampered cell 
proliferation and/or cytotoxic effects or non-specific necrosis. To investigate whether 
cells were dying through apoptosis, we could examine the cleavage of poly-ADP ribose 
polymerase (PARP)，a biochemical hallmark of apoptosis. The trend of decrease in 
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cell proliferation and cell migration observed may be explained by the fact that the 
effect of inhibiting indivdiual miRNA separately was not enough to deduce a 
significant effect in the functional aspects. In fact, it was reported in another study that 
treatment with a mixture of all three miRNA inhibitors of this cluster led to a more 
significant inhibitor! on proliferation in HCC cell lines than treatment with each of the 
individual miRNA inhibitors (Li et al. 2009). Also, as mentioned in earlier chapters 
that miRNA within a cluster may work in a cooperative manner, therefore, it may be the 
reason as to why the changes observed were subtle. To further confirm the effect of 
miR-106b-25 cluster in cell growth, we performed the MTT assay followed by 
overexpression of miR-106b in DAOY. The data were as expected demonstrating a 
� reverse phenotype for over-expression of the miR-106b when contrasted to inhibition 
of the miR-106b. Although the overall effect of miR-106b-25 cluster on certain 
functional properties demonstrated in this chapter may be subtle, yet shifting one set of 
miRNA in vitro may be compensated by other systems, as the pathogenesis of cancers 
is consisted of complex overlapping networks of many pathways. It is unlikely that 
the observed phenotypes of MB are solely caused by one set of abberantly expressed 
miRNA, and most of the time, they are accumulatives of series of secondary effects 
(Ivanovska et al. 2008). It is still too early to draw conclusions on the importance of 
this cluster of miRNA in the functional properties of MB，as there are still other tests yet 
133 
to be investigated. It is possible that the miR-106b-25 cluster act as fine-tuning 
modulators contributing to the tumorigenesis of MB. 
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CHAPTER 6: CONCLUSION 
It was not until Ferretti et al's microRNA profiling in human MB conducted in 
2009 that microRNA expression was first thoroughly studied in MB (Ferretti et al. 
2009). In the study, miRNA expression pattern distinguished tumours in a more 
specific manner, correlating tumour molecular features and disease risk stratification 
(Ferretti et al. 2009). In addition to the miRNA profiling, more emphasis was put on to 
the identification of target genes that are regulated by the aberrantly-expressed 
miRNAs. These targets may be used as novel molecular targets for less toxic and 
patient-tailored therapeutic strategies (Onvani et al. 2010). In this thesis, we have 
employed both the computational and experimental approach to identify target for the 
miR-106b-25 cluster. It is interesting that there were no overlaps between the 
common targets predicted by the computational method and the target genes that were 
isolated by the experimental strategy. In fact, in a study of over-expression and 
inhibition of miR-140, none of the gene discovered were predicted by computational 
approach (Orom and Lund 2010). Together with our observations, it is suggested that 
there still exist a significant number of false negatives excluded by the computational 
approach. Nevertheless, both the computational and experimental strategies have led 
us to the identification of target genes regulated by the miR-106-25 cluster. It is 
difficult to judge whether one approach is better than the other as more trials are needed 
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to conduct to find out their efficiencies. Perhaps, the best route is probably a 
combination of the two. Also, we have demonstrated that dysregulation of the 
miR-106-25 cluster exert significant effect on cell growth in DAOY. Although the 
exact causes responsible for the altered cell growth still remain to be elucidated, but our 
data suggest that the miR-106b-25 cluster is an integrated component of cellular 
pathways contributing to the tumorigenesis of MB. 
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